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ABSTRACT 
 
As Tanzania government is planning to expand point of care services to all primary 
health clinics, it is important to assess the current situation of implementing CD4 
testing at the point of care, which is likely to be repeated under similar conditions in 
other clinics. Hence the developments of coherent strategies for Pima rollout for 
optimal utilization of the device which corresponds to patient care outcomes. This 
study looks specifically at what seems to be the result of offering CD4 testing at the 
Point of Care (POC) in Tanzania with introduction of Pima device. This thesis is 
related to one of the biggest problem of Tanzania health care HIV/AIDS staging.  
The study analyzes both qualitatively and quantitatively observed results, 
demonstrates potential for POC CD4 testing to improve staging of disease and as 
consequence clinical care and timely treatment.  It also shows that the introduction of 
the Pima device dramatically reduced the number of patients turned away. Though 
significant improvements in clinical outcomes were observed after the introduction of 
the Pima device, these improvements were mitigated by the implementation 
challenges leading to the benefits being compromised. 
The results of the thesis have the potential for immediate application in the healthcare 
system in Tanzania and will help to show the benefits of quick and reliable new type 
of CD4 detection equipment. This in turn would be beneficial to the HIV positive 
people seeking treatment. 
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CHAPTER ONE 
1.1 Introduction 
 Tanzania is formally twelfth-highest HIV prevalence in the world, with 5.6% of the 
population infected, the epidemic has stabilized in the last ten years, and begun to 
decline (UNAIDS, 2010). It is estimated that nationally, approximately 1.4 million 
people live with HIV, with an expected increase in cases in rural areas due to 
systemic poverty (UNAIDS, 2011). The majority of these people are adults in 
childbearing age (UNAIDS 2010, 180-186). The number of Tanzanian women living 
with HIV is higher than their male counterparts, with 730,000 representing the former 
and 470,000 the latter. African women have a risk 1.3 times higher than African men 
in contracting HIV, due to cultural and biological factors (MoHSW, 2007, 2). The 
main modes of transmission include heterosexual sex, and mother-to-child-
transmission (UNAIDS, WHO, UNICEF, 2011). 
A range of factors including poverty, inequitable gender norms and early marriage 
has fuelled the spread of the epidemic (USAID, 2012). Poor Tanzanians are 
particularly at risk because they often lack knowledge of HIV treatment and 
prevention. In 2003 the government developed Health Sector Strategy on HIV/AIDS 
for 2003–2008. The strategy was geared towards scaling up antiretroviral therapy to 
the district level and enables the enrolment of up to 15,000 clients on care and 
treatment (NACP, 2008). In response to rising numbers of People Living with HIV 
(PLWHIV) with low enrolment rates into care and treatment, the government 
developed and implemented a plan for providing ART services to all eligible patients 
by the end of 2008. The plan was aimed to place 440,000 HIV patients on ART and 
1.2 million people on care by December 2008 (NACPT, 2009). To accomplish this 
goal, the MOHSW decentralized care and treatment services from district hospitals to 
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primary health clinics. By the end of 2010, a total of 1100 health facilities had begun 
providing care and treatment services. Of those, 220 are hospitals and the remaining 
880 are primary health facilities (UNGASS, 2010). This decentralization has 
increased the demand for ART services, and consequently, the demand for CD4 tests, 
both for initiation into care and treatment, and monitoring of ART-initiated patients. 
Currently on average, 52% of persons with HIV infections who are receiving care and 
treatments are receiving ARVs (UNGASS, 2010). It is clear that the country need to 
improve access to ART and by improving CD4 access may help. Prior to the 
introduction of point of care, Tanzania had limited CD4 test capacity available only at 
the hospital level which was inaccessible to the rural communities (Zachariah R. et al, 
2011).  
The introduction and expansion of POC testing can therefore help to overcome 
logistical and geographic barriers to full-scale roll out of HIV treatment and care, 
increasing the number of patients on ART and reducing HIV-related morbidity and 
mortality. Therefore this work intends to assess the impact of introducing POC for 
CD4 testing in primary health clinics in Tanzania. 
1.2 Facts about Tanzania 
1.2.1 United Republic of Tanzania Country profile 
The United Republic of Tanzania is located in East Africa and is the largest east 
African country when measured in land area. Tanzania is bordered by Kenya, 
Uganda, Rwanda, Burundi, the Democratic Republic of Congo, Mozambique, Malawi 
and Zambia (see figure 1.1) 
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Figure 1.1:  Map of Tanzania 
 
Source: http://www.tanzania-consulate.dk/map.htm (accessed online November 10, 
2012). 
The United Republic of Tanzania is the outcome of a union between two former 
African states, Zanzibar and Tanganyika. Tanganyika became an independent state in 
1961, and Zanzibar got hers in 1963. On the 26th of April 1964 the two nations united 
to form the United Republic of Tanzania.  
Despite the merger 49 years ago, Tanzania still has two-tier government: the Zanzibar 
Revolutionary Government and the Union Government. Dodoma acts as the country’s 
political capital, while Dar es Salaam is considered the country’s commercial capital. 
Its political system is based on a multiparty democracy. The country has 26 
administrative regions, subdivided into 130 administrative districts (The United 
Republic of Tanzania National Website 2011). In Tanzania tribal languages are 
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widely spoken, however, Swahili serves as the lingua franca (Mrisho et al. 2007, 
863).Tanzania has a tropical climate with one wet and one dry season, which occur at 
different times of the year in different parts of the country (The United Republic of 
Tanzania National Website 2010). The rainy season has a sizable effect upon the 
accessibility of the roads and therefore to the health facilities.  
1.2.2 Demography 
1.2.2.1 Socio- demographic Characteristic 
Table 1.1 Tanzania Mainland demographic indicators with HIV assumption 
Statistics  2012 2005 2015 2025 
Annual  population 
(000) 
43,726,471 35,746,092 47,521,276 61,753626 
Growth rate % 2.85 2.89 2.73 2.61 
Total fertility rate 
(births per women) 
5.34 5.66 5.21 4.74 
Crude Birth rate (per 
1000 population) 
41.4 44.9 39.3 35.9 
Crude death rate (per 
1000 population) 
13.5 16.4 12.6 10.1 
Life expectancy at birth 
(years) 
52 49 52 56 
Infant mortality rate 
(per 1,000 births) 
70.5 82.1 65.9 50.1 
Under 5 mortality rate 
(per 1,000 births) 
51 (2010 estimate) 68 88 (1995 Estimate) 
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Source: (NBS, 2006) Tanzania Bureau of statistic, population division, national 
projection (2006). 
HIV/AIDS is a demographic issue as it has effect on mortality and fertility which 
leads to the changes in the other demographic indicators like population growth and 
size.  The total fertility rate of the women aged 15-45 in Tanzania decline from 6.3 in 
1992 to 5.7 in 2005 and to 5.4 in 2010 (THDS, 2010). The main reasons for the 
decline were due to death before the childbearing age, physiological means, use of 
condom and women empowerment.  
Death from AIDS will mean a small proportion of the population surviving to 
childbearing age, with HIV/AIDS assumptions the projection indicate that Tanzania 
population growth rate will decrease  by 2%  by 2025 (NBS, 2006). Death and 
decreasing of fertility rate will have general effect on population growth and size, 
negative population growth with absolute decrease in population number, which will 
eventually affect population pyramid. Therefore mortality, change in fertility and 
behaviour have impact on current predicted data for population. Although the 
prevalence of major diseases appears to be declining, the current HIV/AIDS 
prevalence rate may have been one of the major contributors to the slow increase of 
life expectancy in Tanzania. However, with substantial decline in child mortality, it is 
projected that on average, people in Tanzania have improved their life expectancies 
significantly. Reduction of child mortality rate estimated to increase life expectancy 
by 5-10 years (Demographic Surveillance Site 1999-2007). Using National Bureau of 
Statistics (NBS) projections, it is now estimated that life expectancy in 2012 is around 
57 for males and 59 for females (NBS, 2012).  
Maternal Death per 
100,000live births 
Slight decrease in maternal mortality rate from 578/100,000 live 
birth to  454/100,000 live birth (2009/10) 
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 1.2.2.2 Human Development Profile 
A. Education 
Table 1.2: Tanzania Education Profile  
Indicator Year Values 
Adult literacy rate (both 
sexes above the age of 15) 
2002-2007 72% 
Education attainment  
between males and females 
2009/10 Male 27%, Females 18% 
Median number of years of 
schooling 
TDHS 2009/10 Female 3.6, Males 4.6 years 
Attend in school by age of 20 
years 
TDHS 2009/10 Males 27% , Female 10% 
Attendance rate peak  at age 
of 11 
TDHS 2009/10 9 in 10 male and female 
attending school 
Human development index, 
ranking 2011 
2010 148 
Source: Tanzania Demographic and Health Survey, 2010 
In Tanzania there is a gap in education attainment between females and males; 27% 
of females have never attended school compared to 18% of males. This is because 
culturally education is more important to males than females. The median number of 
years of schooling is differing among males and female, female had 1 year less than 
males. Attending school also differ between male and female with age. 27% of male 
attend the school compared with only 10% of female by the age of 20. Education 
attainment vary across the regions and it’s based on wealth quintiles e.g. 7% of 
females from wealthier households have never been to school compare to 46% of the 
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poorest household (TDHS, 2010). 
B.  Economy: 
Table: 1.3 Tanzania Economic Profiles 
Statistic  % Or  Number Year 
GDP Per Capita $ 552 2010 
Real growth rate 6.4% 
GDP: Composition 
by sector  
Agriculture 27.8 2011 
Industry 24.2 
Services 48% 
Labour force  24.06 million 2011 
Labour force by 
occupation  
Agriculture 80% 2002 
Industry 20% 
Services 
Unemployment rate 2.3 million (12.9 of labour force) 
Source: World Fact book. Tanzania economy 2012 
HIV/AIDS is closely related to economic development. HIV/AIDS is negatively 
affecting economic growth which limits the country to fight against it. HIV related 
mortality and morbidity rate have economic effect at all levels of society, from the 
individual through to the government level. For example individual level economic 
repercussion may include the allocation of resources to the healthcare and funeral. 
The study done in Tanzania showed that 8% of the total household expenditure was 
allocated to medical care and funerals in a  household that had an adult death in the 
preceding 12 months (Mead Over et al. 1996). Reduced in labor force as a result of 
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death, care of the patients and funeral duties hence reduced productivity and increased 
cost for companies, reduction in household income due to increased AIDS related 
expenditure and increase in government budget deficit due to increased health 
spending (Bollinger L, Stover J, & Riwa P, 1999). 
C. Poverty  
Table: 1. 4 Incidence of Poverty in Tanzania (Poverty Head Count Index) 
 
Item Year Dar-es 
Salaam 
Other 
Urban areas 
Rural areas Tanzania 
Mainland 
Food 2000/1 7.5 13.2 20.4 18.7 
 2007 7.4 12.9 18.4 16.6 
Basic needs 2000/1 17.6 25.8 38.7 35.7 
 2007 16.4 24.1 37.6 33.6 
Source: International Monetary Fund. (2010). Tanzania: Poverty Reduction Strategy 
Paper.Washington, D.C. International Monetary Fund. 
It is estimated that approximately 50% of the population in Tanzania is living below 
the poverty line (The United Republic of Tanzania National Website 2012). Poverty 
in Tanzania occurs predominantly in rural areas. However, poverty in the urban areas, 
mostly due to unemployment and employment in informal sectors, is growing rapidly 
(The United Republic of Tanzania National Website 2011). The poverty is associated 
with the lack of quality education, capital and human assets. Other factors include 
large families, a large part of the population suffering from poor health, and a high 
vulnerability to diseases, including HIV/AIDS. 
  9 
 
D. Health  
Table: 1.5 Health systems indicator 
Item Amount Comment 
Financial Resources Proportional of national 
budget spend on health  
Increase from 13.45% 
in 2006/07 to 13.87% 
in 2008/09 
increase in government 
spending on health does not 
reflect the good 
performance of health care 
system 
Total Government and 
Donor on Budget 
Allocation to health capita 
increased from 
17,474.55 to 
24,791.25in 2008/09 
per capita health spending is 
still low compared with 
2015 HSSP III and 
MKUKUTA target which is 
52,800.25 
 
Proportion of population 
enrolled in CHF/TIKA 
6.6% of Tanzanian 
slight increase from 
previous year which 
was 5.6%. 
The MOHSW has a long 
way to reach the target of 
enrolling 80% of Tanzanian 
population by 2015 
Human resource 
status in the Health 
sector  
By December 2010 the total number of health 
workers was 52,637 which is 64% of the actual 
requirement. The deficit was 29,650 (36%) of the 
actual requirement 
Acute lack of medical 
personnel is a national issue 
Source: Tanzania Ministry of Health and Social Welfare 2010 
HIV/AIDS has increased burden to the health care system of all the countries 
worldwide but sub Saharan Africa region is mostly affected. The disease has reduced 
the resources for solving other health related problems, which had an effect of overall 
quality of health services. In Tanzania where by human and financial resources are 
constrained, additional HIV care and management services has added challenges to 
the health system. Today more than 80% of hospital admissions are HIV related 
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conditions (NACP, 2012). HIV has also affected health care workers and thus an 
additional burden has been felt. 
E. Medicines and laboratories 
Essential medicines are supposed to be available in all primary health care facilities 
but unskilled personnel who have low knowledge on quantification and forecasting 
manage most of these facilities. Sometimes the zonal medical store does not have all 
essential drugs for facilities.  The introduction of push system makes the situation 
even worse. 
Laboratories are supposed to be available in level two of primary health care but not 
all the health centres have laboratories and it’s due to shortage of laboratory 
technicians and laboratory equipment. At Districts, Regional and National level 
laboratory equipment and machines are not enough, which leads to long cue and 
waiting time (THDS & ICF Macro, 2009/10). 
1.2.3 Overview of the health care system in Tanzania 
The health care system in Tanzania is built hierarchically, with the following levels: 
Village health services, health dispensaries, health centres, district hospitals, regional 
hospitals and referral hospitals. Health workers who are given a short training provide 
village health services, and the services are provided within the home (The United 
Republic of Tanzanian National Website 2011). The health dispensaries are numerous 
and are located within villages to facilitate easy access. These facilities are intended 
to serve between 6,000 and 10,000 people. Dispensaries provide various services, 
ranging from dressing of wounds to infant delivery. Health centres are larger units 
intended to cater to more than 50,000 people. Many health centres have wards for 
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patients to stay in and labour rooms. Each district has a district hospital, and all 
regions in the country have a regional hospital. There are four referral hospitals which 
provide the highest degree of hospital services in Tanzania. Not all facilities offer 
HIV related care and treatment services. Patients in need of this service are referred to 
facilities having a care and treatment clinic (CTC), which among other services 
provides HIV drugs, counselling on infant feeding etc. (Ministry of Health and Social 
Welfare 2010, 10). 
1.2.4 Overview of Point-of-Care Testing in Tanzania 
In January 2012, the National AIDS Control Program (NACP) implemented a plan to 
standardize and expand the use of POC CD4 testing in Tanzania. POC CD4 testing is 
rollout in phases, beginning with the Alere Pima, which was introduced after a 
successful technical evaluation, and initial pilot in Lindi and Mtwara carried out by 
the Clinton Health Access Initiative (CHAI) and the NACP. Devices have been 
placed at 254 sites as of September 2012, in 21 regions across Tanzania, with the 
largest number of devices in Tanga, Tabora, Mbeya, Kagera and Kilimanjaro regions. 
Current guidelines in Tanzania recommend prioritizing Pima rollout to sites with high 
patient volumes, to impact the greatest number of patients and take advantage of 
scaled cost-savings. However, many devices were rolled out prior to the publication 
of this protocol, and these POC CD4 devices were placed primarily in rural areas, 
which have the highest rates of LTFU. There is a significant rural bias to the 
placement of Pima devices in Tanzania, which is reflected in the sites chosen for this 
study.  
According to the most recent census, 26% of Tanzanians live in urban centres, with 
the remaining majority of the population in rural areas and villages (CIA, world fact 
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book, 2011). However, HIV prevalence is higher in urban areas than rural areas (8.7% 
and 4.7%, respectively (USAID, 2012). As of 2010, the most recent year for which 
data is available, there were seven FACSCalibur and 74 FACSCount units in 
Tanzania. Currently referral hospitals in Tanzania have the highest-throughput device 
(the FACSCalibur), while regional and district hospitals have FACSCount machines. 
The Ministry of Health and Social Welfare had a plan of rolling out Pima services to 
5 to 10 sites at regional level, 100 sites at district level and 600 sites at primary health 
clinics. 
1.2.5 Health care financing in Tanzania 
Previously Tanzania health care system was purely financed by the central 
government. The public financing was not enough to maintain the existing health 
structure and in 1993 the government introduced user fees with the aim of increasing 
resources available for health care system while removing the notion that health care 
is free, to help to avoid unnecessary visits and informal payments. The user fees made 
access to health care services relatively more expensive for poorer people than for 
richer people. Although exemption and waiver were in place to ensure access of 
services to the poor, the reviews of those polices indicated that the desired effect were 
not met (Mtei and Mulligan 2007, 47–48). The reviewers found that the system 
favoured well off people rather than the poor.  A household survey conducted by the 
SHIELD project estimated that 44% of those who were eligible for exemptions pay 
user fees for outpatient care; 70% pay for inpatient care. For those not eligible for 
exemptions, 89% pay for outpatient care and 86% for inpatient care (Borghi, Mtei, 
and Ally 2011, 39). Thus, exemptions are somewhat effective in reducing out-of-
pocket payments. With respect to waivers, the poorest often do not have access 
because of a lack of information, denial of the waiver by a provider, loopholes that 
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allow misuse and sometimes abuse of the system, and a lengthy and cumbersome 
identification process that often deters people from applying for waivers (Mtei and 
Mulligan 2007, 6). Identification of the poor is a major problem, because there are no 
clear guidelines and no money has been set aside by the government to compensate 
facilities for waivers. In addition to exemptions and waivers, other systems were 
developed to address the highly regressive aspects of user fees, thus enabling people 
to access medical treatment when needed through prepayment and risk pooling. The 
mechanisms included voluntary public community health funds organized at the 
district level, voluntary micro-health schemes organized at the community level, 
private health management organizations, private health insurance, public mandatory 
social health insurance through the NHIF, and voluntary health benefits through the 
NSSF. Whereas the NSSF itself is mandatory, members must sign up separately for 
the SHIB health benefit but most do not. Since then the health financing system of 
Tanzania is highly fragmented with many financers and mode of financing. 
HIV/AIDS is mainly funded by development partners and services such as 
diagnostics and drugs are provided free of charge. In summary, the health financing 
landscape in Tanzania is quite fragmented, with a large number of funding sources 
covering different aspects of the costs of health services. The HSSP III has as a major 
priority the development of a comprehensive health financing strategy to determine 
the appropriate mix of financing modalities and to develop a road map for improving 
financial and physical access to health services by all Tanzanians. Criteria should 
therefore be developed for identification of poor people who are in need of waiver 
and exemption to access health care services. 
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1.2.6 Coastal Regions 
There are 26 administrative regions in Tanzania, with a population estimated to be 43, 
726,471 in 2010(NBS, 2012).  The regions are divided into districts of which each 
region has between 6 to 8 districts. The poverty situation differs from one region to 
another.  According to poverty and welfare rankings, Lindi region is ranked as one of 
the most deprived regions in Tanzania together with Dodoma, Kagera, and Pwani 
Regions (The Government of Tanzania, 2011). There are few paved roads rural areas 
of most of the regions. Some roads are not passable during rainy seasons and some 
others are too steep for cars to get through at all (Mrisho, Mwifadhi, Joanna A, 
Schellenberg, Adeil k. Mushi, Brigit Obrist et al, 2007). All regions have regional 
hospitals and all districts have district hospitals and within the districts there are 
primary health clinics (health centres and dispensaries) with about 90 percent of the 
population living within 5 kilometres away from a primary health facility (Tanzania 
MoHSW, 2008). There are 4 referral hospitals in Tanzania and the regions supported 
by those hospitals are divided by zones. For example all the coastal regions of 
Tanzania are served by Muhimbili National Hospital located in Dar es Salaam. The 
study was within five coastal regions of Tanzania Mainland which are Tanga, Pwani, 
Dar es Salaam, Lindi and Mtwara. The five coastal regions of Tanzania mainland 
encompass about 15% of the country’s total land area. Approximately 25% of the 
country’s populations live in these regions (NBS, 2010). Most of the coastal 
communities are very poor with less than US$100 per capita GDP at current prices 
(NSGR, 2005). The HIV prevalence vary from one region to another with 9.3% in 
Dar es Salaam, 3.8% in Lindi, 3.6% in Mtwara, and 6.7% in Pwani and 4.8% in 
Tanga  (TACAIDS, 2008). Based on the selection criteria, the researcher managed to 
visit 4 out of the five regions (Lindi, Mtwara, Pwani and Tanga). 
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Why the study has to focus on the coastal region? 
The study focused on the coastal regions because it is the area where Pima device has 
been placed in the clinics at least six month ago, with a big volume of patients. The 
regions are also easily accessible.  
Figure 1.2: Map of Coastal Regions 
 
Source: http://coastalforests.tfcg.org/images/tz-regs.gif 
 
1.3 Problem Statement 
Though CD4 testing is the entry point to HIV/AIDS care and treatment, still there are 
considerable barriers to access in resource limited settings. Testing facilities are 
centralized and require highly trained and specialized infrastructure (UNITAID, 
2012). Primary health care workers who wanted to order CD4 test were faced with a 
lots of challenges. As a result, patients were often lost due to repeated visits to the 
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health facilities as well as delays in returning results (MOHSW, 2010). A study in 
Mozambique found that CD4 staging on a traditional CD4 machine could take up to 4 
to 6 weeks (Jani et al, 2011). To address this challenge, the MoHSW introduced at 
primary health care levels, Pima point of care for CD4 testing so that those found 
positive can be appropriately managed. Pima point of care was introduced about one 
year back; this was done after it was confirmed that its tests were accurate in 
comparison to traditional CD4 machine. There has not been a tangible evaluation 
since they were introduced. This reality made the government to hesitate to continue 
the rollout of the device. This is a major gap and there is a need to collect evidence 
whether PIMA is successful or not. The outcomes of this particular study will fill this 
gap by providing a fair and timely evaluation of the impact of implementing CD4 
testing at the point of care on HIV case management in primary health clinics. The 
thesis tries to provide an answer for what one such intervention has led to. It will also 
help to gain knowledge of which conditions have led to the results found, and what 
actions can be taken in future in order to make such interventions successful. 
1.4 Rational of the study 
This study will provide evidence as to whether the introduction and use of PIMA 
point of care for CD4 testing in primary health clinics has improved HIV case 
management. The report will be widely disseminated and meetings will be held in all 
study regions of Lindi, Mtwara, Pwani and Tanga. Based upon the data, discussion 
with relevant stakeholders will be conducted to adopt new direction if needed 
regarding PIMA. Additionally the Tanzania Ministry of Health and Social Welfare – 
Director of Curative Services, NACP Manager and partner organizations will also 
receive the report and recommendations. The aim is to provide a platform for 
developing new or modifying policies regarding HIV case management. The report 
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will also provide critical information to service providers and planners that will help 
them in selection of technology, design services and allocate resource efficiently. 
1.5 Research questions 
i. To what extent point of care CD4 testing affects the rate of CD4 count at 
initiation and time to antiretroviral therapy initiation? 
ii. To what extent point of care CD4 testing affects patient retention before 
immunological staging and treatment initiation? 
iii. Does CD4 testing at the point of care affect patient schedule and waiting time? 
iv. Are there any barriers to the implementation of Pima POC CD4 testing in 
primary health clinics? 
1.6 Main objective 
To assess the impact of implementing CD4 testing at the point of care on HIV case 
management in primary health clinics in Tanzania 
1.6.1 Specific objectives 
i. To assess the effect of point of care CD4 testing on rate of CD4 count at 
initiation and time to antiretroviral therapy initiation. 
ii. To assess the effect of point of care CD4 testing on loss to follow up before 
immunological staging and treatment initiation. 
iii. To determine the impact of CD4 testing at the point of care on patient 
schedule and waiting time.  
iv. To identify barriers to the implementation of Pima in primary Health clinics 
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Figure 1.3: Conceptual Framework of POC testing in comparison to tradition 
laboratory base testing and its impact 
Clinic collects patient 
sample1
Samples sent to district 
hospital
District Hospital runs labs
Results returned to clinic
Clinics receive 
results, patients return to 
collect results
Repeat every 6 months for patients with CD4>350 L, or initiate 
onto ART for patients with CD4<350 L,
Delays 
possible due to 
hospital 
capacity
Delays 
possible due to 
sample loss
Delays 
possible due to 
defaulters 
Delays 
possible due to 
transport 
schedule
Patient provides 
sample
Patient receives 
results (20 
minutes)
Patient is initiated 
onto ART or 
asked to return in 
6 months
POCCD4 technology simplifies the sample collection process for patients and providers
Traditional lab-based testing POC testing
1Note: in lab-based testing patients must schedule 
sample collection, usually once per month.
Source: Researcher’s own design 
 In Tanzania individuals walk for over five hours to get to a comprehensive primary 
health clinic in the remote areas. No paved roads and the public transport systems are 
almost inexistent with the majority using bicycles and motorcycles as the means of 
transport and anyway unaffordable. When the HIV positive individuals are in need of 
CD4 count, they are scheduled for blood collection which is usually done once or 
twice per month at a clinic level. Then clinic collects patient samples and sent away 
using existing means of transport (can be bus, private car, bicycle or motorcycle). The 
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HIV patients are told to come back 2 weeks later to get results. A study in 
Mozambique found that CD4 staging on a traditional CD4 machine could take up to 4 
to 6 weeks (Jani IV et al, 2011). 
The samples are sent to the district hospital and delays are possible due to Machine 
malfunction as a result of poor maintenance, breakdown, and shortage of staff and 
lack of reagents due to stock outs or financial constraints. They had many additional 
challenges such as blood specimen being damaged or unsuitable for testing because of 
delays in sample reaching the CD4 count laboratory, poor handling, or lose of the 
results due to unclear records management system.  
Patients getting CD4 testing require repeated visits to the health facilities leading to 
delays in accessing ART and in most cases lost to follow up due to lack of transport 
and financial constraints. By the time the results are ready the patient is too sick to 
return to the clinic or overwhelmed due to disturbances. Such individuals are usually 
impossible to track them again, thus they end up being declared as “lost to follow up,” 
which exceeds 50% in low-income settings, and it is a significant barrier to the scale-
up of HIV treatment (Jani IV et al, 2011). This is the situation for Tanzania, a country 
that ranks 25th on the scale of highest HIV prevalence in the world. This means the 
traditional CD4 technology used was inappropriate technology that was inaccessible 
for rural communities (Zachariah R. S, 2011).  
The Alere Pima device enables clinicians to provide patients with an absolute CD4 
count within twenty minutes and therefore can initiate them into ART within the same 
day or asked to return in six months (Mtapuri Zinyowera, S. et al 2010 & Zachariah 
R.S, 2011).  
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Figure 1.4: Research Framework 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Researcher’s own design (Diagram was contracted based on patient flow at 
the clinic level). 
All patients found to be HIV positive at the clinics are referred for enrolment into 
HIV Care and Treatment Clinics (CTC). After enrolment, patients are referred on the 
same day to point of care for CD4 testing and obtain the results within 20 minutes. 
Then patients who are eligible for ART based on the CD4 test results have to come 
back for three pre ART counselling, hemoglobin and liver function test before 
initiation of antiretroviral therapy. Before the introduction of point of care test, blood 
samples were collected once or twice per month and sent to nearby laboratories. 
Patients were then asked to return for a staging visit after the test results were 
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available. If eligible as a result of CD4 cell count or clinical sign, a patient usually 
has three counselling visits, hemoglobin and liver function test before initiation of 
antiretroviral therapy. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Global situation of HIV/AIDS 
The world today is facing serious challenges regarding the HIV/AIDS epidemic. In 
2010 worldwide 34 million people were living with HIV (UNAIDS, WHO, UNICEF, 
2011). Several indicators have demonstrated the improvement in combating the AIDS 
epidemic (UNAIDS, 2010). Despite the improvement, still the world is facing some 
challenges of low levels of enrolment into treatment. The global HIV burden is 
unevenly shared with an estimated 23.5 million people living with HIV found in sub 
Saharan Africa, among them 1.9 million were newly infected in 2010. Sub Saharan 
Africa is home to only 10% of the world’s population (UNAIDS, 2010). Great 
inequalities occur in prevalence rate among nations within the sub Saharan Africa, 
from the Comoros with 0.1% to Swaziland with 25.9% (UNAIDS, 2010). Despite the 
notable global effort to improve access to ART, approximately 50% of the people 
who are in need do not receive it (WHO, 2012). Access to antiretroviral medicines is 
needed for preventing morbidity and mortality including mother to child transmission, 
access to CD4 testing may improve the situation. 
2.2 Laboratory test for HIV and AIDS 
A person with HIV needs a comprehensive clinical care which requires health care 
personnel to have appropriate clinical knowledge, experience and laboratory support 
to identify patients with gross features of HIV disease. Laboratory testing is an 
integral part of HIV and AIDS care and treatment. These tests provide additional 
information on individual status, the level of disease progression, treatment eligibility, 
response to treatment and drug adverse reactions. A package of affordable diagnostic 
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tests, performed at the point of service delivery is needed for further rollout of HIV 
testing. This would help reduce instances of late initiation of antiretroviral therapy 
and ensuring adequate monitoring of lifelong HIV therapy in particular in primary 
health clinics (UNITAID, 2012). 
2.2.1 Test for HIV diagnosis 
The HIV diagnosis for adult and children above 18 month is done by the detection of 
antibodies to HIV using rapid tests. The national rapid alogarism for Tanzania is 
made up of the following rapid tests: - Determine HIV ½ and Uni-Gold HIV. Rapid 
test can be done using whole blood, serum or plasma sample and can be performed in 
laboratory and non-laboratory settings such as hospitals, clinics and in the community 
by trained staff (Kedrick et al, 2005). Rapid HIV testing are available in Tanzania and 
accessible to the rural communities. For distant communities the testing is done 
through mobile clinics. 
2.2.1.1 Diagnosis of children under 18 month 
Diagnosis of HIV infection in children below 18 month to determine whether he/she 
has been exposed is done by detection of viral nucleic acid (RNA or pro viral DNA) 
or viral antigens. HIV DNA polymerase chain reaction (PCR) is used in Tanzania to 
confirm HIV infection in infants by the age of four weeks and children below 18 
month. Capacity for PCR testing is limited in the national level and it is a challenge to 
paediatric enrolment into care and treatment in Tanzania. The recent point of care of 
dried blood spots for quantifying viral load and early infant diagnosis has 
demonstrated promising results (UNAIDS, 2011).  
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2.2.2 CD4 testing for disease staging and monitoring responses to ART 
Patients are supposed to receive CD4 test immediately after testing HIV positive to 
check ART eligibility and after ART initiation to assess the treatment outcome. In 
adolescents and adults, CD4 counts are reported in absolute numbers while for 
children under six years are reported in % (WHO, 2010). WHO recommends ART 
initiation if CD4 counts are below 350 and for under-five years old if the CD4% of 
lymphocytes is less than 15-25% (WHO, 2010). Once the patient is eligible for 
treatment they are planned to have their CD4 count routinely every 3 to 6 months, and 
those who are not yet eligible are monitored in every 6 to 12 months. Perhaps Patients 
on ART are received up to 50 CD4 counts (Peter T et al, 2008). Therefore the demand 
for CD4 count test will continue to increase as the government continues to scale up 
ART services to the rural community. International and national guidelines 
recommend the use of CD4 count for treatment decision and marker for treatment 
outcomes in both adult and children (WHO, 2006), (NACP, 2012). When available, 
viral load may be considered in addition to clinical and immunologic measurements 
to diagnose treatment failure earlier. However, capacity for viral load measurements 
is currently limited (NACP, 2012). 
Table 2.1: Laboratory monitoring before, during and After Initiating ART 
Phase of HIV management  Recommended test Desirable test 
AT HIV diagnosis CD4 HBsAg 
Pre-ART CD4  
At start of ART CD4 Hb for AZT creatinine 
clearance for TDF, ALT 
for NVP 
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On ART CD4 Hb for AZT, creatinine 
clearance for TDF, ALT 
for NVP 
At clinical failure CD4  
At immunological failure Viral Load  
Women exposed to PMTCT 
interventions with sd-NVP 
with a tail within 12 months 
and without a till within six 
month of initiating ART 
 Viral load six months 
after initiation of ART 
 
   Source: Tanzania HIV Care and Treatment guideline- 2012. 
2.2.3 Tests for Monitoring Antiretroviral Treatment Toxicity 
Though ART has the potential to control HIV and save lives, the drug cocktails can 
also cause serious side effects, which must be monitored. AZT can cause anaemia, 
which can be monitored with regular Hemoglobin testing (currently available in POC 
form with the Hemocue device). TDF can cause renal function, necessitating 
creatinine testing. NVP can cause hepatotoxicty, which can be monitored with ALT 
tests. Baseline testing is a vital indicator of which regimen to choose, and continuous 
monitoring testing can preserve health status for patients, while preventing the 
development of life-threatening complications. It is vital, therefore, to ensure that 
these complementary tests are occurring regularly. Capacity for testing haematology 
indices and clinical biochemistry has been developed at the laboratories of all 
hospitals with a CTC in the country but not in all primary health clinics (NACP, 
2012). 
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2.3  Pima Device 
 
The Alere Pima device enables clinicians to provide patients with an absolute CD4 
count within twenty minutes. Designed for use in the resource-constrained setting, the 
device can be operated with an external power source, rechargeable battery, or solar 
charger. The unit uses disposable test cartridges with sealed reagents, ensuring safety 
and effectiveness.  
The Pima test consists of a disposable test cartridge containing dried reagents, and the 
Pima analyzer (Vanjari et al, 2011). Approximately 2L of capillary or venous whole 
blood is collected into the test cartridge, and the sealed sample is then processed. The 
test result displays on the front of the unit when the test has been completed, and the 
results are saved on an on-board archive that can be retrieved and downloaded by the 
user at any time after the test (Boyle SD, Hawkins RK, Steele SM, Singhal M, Cheng 
X, 2012). 
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Table 2.2: Comparison of Pima POC CD4 to Conventional Testing 
Category Conventional Lab Testing Pima POC Testing 
Turnaround Time 1 day – 2 weeks 20 minutes  
Throughput 50-300 tests per day 20 tests per day 
Amount of Training Required 2-30 days ½-3 days 
Electricity Required Yes No 
Refrigeration Required Yes No 
Sample Transportation 
Required 
Yes No 
Supply Chain Requirements Many consumables Few consumables 
Sample Type Venous blood 
Capillary or venous 
blood 
Instrument Cost $20,000-$75,000 $5,000 
Test Cost Typically $6-10 per test 
$10 at high-volume sites 
$20 at low-volume sites 
Visits Required for Single Test 2 1 
Loss-to-follow-up prior to 
initiation onto ART 
Up to 64% in resource 
constrained setting 
33%
27
 
Loss-to-follow-up during CD4 
Staging 
57%
27
 21%
27
 
Instrument Downtime Up to 30% in some labs Low 
Note 27: Massambu, C. Mwangi, C. The Tanzania Experience: Clinical Laboratory 
Testing Harmonization and Equipment Standardization and Different Levels of a 
Tiered Health Laboratory System 
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2.3.1 PIMA CD4 testing 
Based on clinical observations in Pima testing, patients provided blood samples either 
through finger prick or venous blood. “After sample collection through Pima 
cartridge, the cartridge is capped and inserted immediately into Pima analyzer to run 
the test. During the analysis process, the blood is automatically mixed with freeze-
dried fluorescently labelled antibodies (anti-CD3 and anti CD4) contained in the 
cartridge and transferred to a detection chamber were images are taken of the 
labelled cell to calculate the number of CD4 cell per L of blood. The results are then 
printed and recorded after each test” (Mtapuri Z. S. et al. 2010) 
Figure 2.1 Point of care CD4 testing procedure overview 
POC CD4 Testing Procedure Overview:
1. Sample 
collection
2. Run 
sample
3. Run sample using standard 
machine for comparison and 
repeatability
 
Source: Tanzania Ministry of Health and Social Welfare, 2011 
2.3.2 Cost Discussions 
Reagent costs for POC CD4 testing slightly exceed those for traditional laboratory-
based testing, but analysis has shown that at average testing volumes, the cost of POC 
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CD4 testing is comparable to traditional CD4 testing. Based on Clinton Health Access 
Initiative (CHAI) Laboratory Service Team analysis in 2011 conducted over several 
countries in the developing world, when testing volumes rise above 2850 tests/year 
(11 tests per day), POC cost per test is less than conventional CD4 testing.  
           Figure 2.2: Point of care cost per test 
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cheaper than conventional CD4
                 Source: CHAI Laboratory Service Team analysis in 2011 
The same study showed that with average volumes of 1,400 tests per year (~5/day), 
POC CD4 tests cost $11.81 per test, as compared to $10.56 for FACSCount testing at 
the district hospital, and $16.75 for FACSCount at the clinic level. The one-time 
overhead costs of acquiring a POC unit are thus spread over an increasing number of 
tests, while conventional laboratory-based testing has a fixed cost. POC testing can 
take advantage of economies of scale, while conventional testing cannot.  
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      Figure 2.3 Point of care cost as comparable to conventional CD4 testing 
$5.60 $5.60 $6.55
$1.09 $1.09
$5.96
$1.95
$2.40
$1.25
$10.56
$16.75
$11.81
$0.00
$2.00
$4.00
$6.00
$8.00
$10.00
$12.00
$14.00
$16.00
$18.00
FACS Count at 
District Hospital
FACS Count at Clinic POC CD4 at Clinic
Human 
Resources
Sample 
Transportation
Lab Overhead
Freight
Equipment
Controls
Consumables
Reagents
At average Clinic volumes of ~1400 tests/year (~5/day), POC CD4 cost per test is 
comparable to conventional CD4 testing
 
Source: CHAI Laboratory Service Team analysis in 2011 
2.4 Emerging of new technologies for point of care CD4 count cell 
Some devices are available now and current studies suggest more devices will be 
released in future. Non point of care machine remain viable in urban and new 
technology which are rapid, easy and cost effective should be developed for rural 
areas and their rollout should accompany with the availability of ART drugs. While 
the development of the new technology continues, capital equipment and human 
resources cost should be assessed for easy adoption and uptake in the resource-
constrain settings.  The development of the technology provides support to the rollout 
of HIV care and treatment program. Evidence based research is needed showing 
challenges faced by the decision and policy makers when making procurement and 
implementation decision (Boyle SD, Hawkins RK, Steele SM, Singhal M, Cheng X, 
2012). WHO, UNAIDS and other partners are in the process to determine the ideal 
package of point of care diagnostics in identify challenges in developing and 
delivering of new technology and speed up the critical path towards making them 
available (UNAIDS, WHO, UNICEF, 2011) . UNITAID committed more than USD 
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140 million to project implementation of point of care services by different partners in 
low income countries. This aims to improve access of diagnostic services to patients. 
The support targeted 3 critical diagnostic tests for HIV such as CD4, early infant 
diagnosis and viral load. In planning to implement point of care services it is crucial 
to consider some of the challenges the program might face especially in the rural 
clinics (Peter T et al, 2008). Therefore the development of the device should be 
consistence with the implementation process.  
2.5 Performances of Pima 
Point of care eliminates the challenges faced with the conventional laboratory based 
services and its utility is not limited to the rural areas. Most of the developing 
countries like Zimbabwe, Mozambique, Uganda, South Africa etc are using Alere 
Pima technology and their performance is good as compares to conventional 
laboratory based technology (Mtapuri Z. S. et al, 2010; Jani I.V. et al , 2011; Manabe 
YC. et al, 2012; Herbert S. et al, 2012; Glencross DK. et al, 2010; Thakar M. et al, 
2012). Pima performance is highly correlated when using venous blood but if the 
finger prick blood sample are correctly collected and tested there is also high 
correlation (Glencross et al., 2012; Alassane PD. et al, 2011; Sitoe N. et al, 2011). 
Skilled health staffs are highly needed for proper sample collection (Herbert S. et al, 
2012; Mtapuri Zinyowera, S. et al, 2010; Kafufu Fred, 2010). Point of care can be 
done by either laboratory technicians or nurses, there is no significance difference 
between the test run by a nurse or laboratory technician, this justify the increase of 
human resources available for Pima services and possibility of implementing it in a 
standalone clinic such as VCT, PMTCT (Mtapuri Zinyowera, S. et al, 2010). Pima 
correctly identified 93% of pregnant women eligible for ART, hence with Pima we 
can reduce mother to child transmission by early initiation of ART to pregnant 
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mothers and promote early initiation based on 2010 WHO recommendations that 
women are supposed to start their ART at early stage of 14 week of their gestation 
(Myani CN, Mclintyre JA, Myer L, 2012). Pima is also good in identifying clients 
eligible for ART as it is highly correlated, with low biases (Sukapirom K. et al, 2011). 
When rapid point of care CD4 testing is provided through mobile clinics, it increases 
linkage to care and patients are likely to visit referral clinics and their results are 
accurately determined with non-clinical bias (Larson AB et al., 2012; Schaik NV et al, 
2011). In general Pima is highly accepted by the clients as it provides rapid results 
which reduce lost and time to the clients (Herbert S. et al, 2012). Efforts is needed for 
the development of new point of care technology especially those which are still 
relying on complicated laboratory infrastructure like DNA-PCR and HIV viral load 
which limit access to rural communities (Anderson AD, Crowe MS, Garcia M, 2011). 
Despite of shortcomings identified, Pima device may be one of the suitable 
instruments for rural communities (Bergeron M, 2012; Kafufu Fred, 2010; Glencross 
et al., 2012). However, proper training and support is highly needed for the operators 
to reduce those shortcomings. 
2.6 HIV Prevention and Treatment 
The government efforts need to focus on both HIV prevention and treatment. 
Antiretroviral treatment has now been seen as having crucial impact on AIDS 
response but this is only true when prevention and treatment interact in synergy. 
Currently we have seen the global impact of promotion and support combination HIV 
prevention that leads to the decline of transmission rate (UNAIDS, 2010). 
Behavioural change is the crucial factor for the decline. The government investment 
on comprehensive and correct knowledge about HIV and condom use and condom 
distribution is crucial. Correct and consistent use of condoms has proven effective in 
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reducing 90% of transmission rate (UNAIDS, 2010). The investments of substantial 
efforts to programming and funds to prevent high risk such as drug users and sex 
workers is highly needed to reduce the infections. Currently the challenge is the 
planners and implementers are reluctant to focus their prevention effort where they 
produce maximum impact (UNAIDS, 2010). New methods for prevention should be 
continued to be adopted such as male circumcision and use of microbicide gel by 
women. Universal access to prevention of mother to child transmission in antenatal 
and postnatal care could eliminate the transmission. Availability of CD4 testing for 
HIV infected individuals is crucial for early initiation of ART and monitoring of drug 
results. Early initiation of antiretroviral prophylaxis to pregnant women can reduce 
HIV transmission from mother to child (WHO, 2010). The government efforts on 
prevention should continue by allocating more resources on prevention to reduce the 
burden caused by high incidence of HIV infection which will include the reduction of 
cost for treatment and diagnostic services. 
Most of the studies mentioned are based on assessment of the accuracy of point of 
care tests and its development. A good number of them are experimental in nature, 
focusing mostly on comparison with the tradition technology, very little was said 
about its impact on HIV case management. However the strength of these studies is 
the fact that they are multi-sited and the study has been done from different under 
developing countries which have almost the same context with Tanzania.  
2.7 Need for and Potential Benefits of Point-of-Care Testing 
Measuring the concentration of CD4+ T-cells in the blood is essential to quantifying 
the level of immune suppression among HIV patients. CD4 count is the most 
commonly used indicator of disease progression, and is a more reliable indicator than 
clinical staging. In settings where CD4 testing is available, it is used to determine 
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eligibility for antiretroviral therapy (ART) initiation and monitoring of ART-initiated 
patients. For all patients older than 5 years of age, CD4 absolute count is 
recommended, measured as the number of CD4 cells per L of blood (WHO, 2009). 
Constrained access to CD4 testing results in late initiation onto ART, which imposes 
costs on patients including additional morbidity and mortality, and poor treatment 
prognosis once initiated onto ART (Larson et al. 2009). Studies have shown that a 
low CD4 count (<100 cells/ μl) at initiation is a major predictor of HIV/AIDS 
mortality (Lawn et al. 2008; Lawn et al. 2009). Immune system recovery after 3 years 
on ART is also positively correlated with a patient’s CD4 cell count at initiation 
(Robbins et al. 2007). A study in Mozambique showed that the expansion of rapid-
response and point-of-care testing increased the percentage of HIV-infected persons 
on ART. The same study found that the introduction of POC CD4 testing decreased 
LTFU from 57% to 21% (Jani et al. 2011). The median time to enrolment on ART 
fell from 48 to 20 days, and the proportion of patients initiating ART increased from 
12% to 22% (Jani et al. 2011). Current WHO ART guidelines recommend initiation 
onto ART for all patients with a CD4 cell count at or below 350 cells per μL. 
However, a recent review of eight sub-Saharan African countries found that median 
CD4 cell count at initiation was 136 cells per μL (Nash et al. 2011). POC CD4 testing 
may enable more patients to initiate ART with cell counts closer to 350 by increasing 
the number of patients who are successfully staged, and by decreasing LTFU prior to 
initiation onto ART (Jani et al. 2011). 
The expansion of POC testing can therefore help to overcome logistical and 
geographic barriers to full-scale rollout of HIV treatment and care, increasing the 
number of patients on ART and reducing HIV-related morbidity and mortality.  
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The potential benefits of POC CD4 testing are as follows: 
Cost & Resource Needs 
i. Reduced delivery frequency due to long shelf life and high-heat stability  
ii. Reduced device cost as compared to traditional laboratory instruments. 
iii. Reduced training and staff requirements due to ease of use and training. 
iv. Reduced infrastructure requirements e.g. smaller space required for device, 
solar charger and battery capability. 
v. Permit task shifting and the use of unspecialized staff. 
vi. Timing. 
vii. Reduced patient burden by eliminating multiple visits for a single test. 
viii. Reduced turnaround time (<20 minutes) by providing same-day test results. 
ix. Eased capacity shortages and backlogs at central labs by diverting samples 
customarily referred for conventional testing. 
Quality of Care 
i. Improved patient outcomes by enabling faster treatment decisions. 
ii. Reduced patient LTFU between HIV diagnosis and CD4 staging, as well as 
between eligibility for and initiation of ART. 
Prior to the availability of POC CD4 devices, CD4 testing was based at Zonal, 
Regional and district hospital laboratories. There are currently 170 sites with labs 
offering conventional CD4 testing, including regional hospitals, district hospitals, and 
some health centres (MoHSW, 2011). 
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CHAPTER THREE 
METHODOLOGY 
3.1 Study Design 
This study was a cross sectional explorative study to evaluate the impact of 
implementing CD4 testing at the point of care on HIV case management in primary 
health clinics in Tanzania. The study was conducted using both qualitative and 
quantitative methods. For quantitative approach a pre-post evaluation was done, to 
compare beneficiary before and after introduction of Pima to see their changes. 
Qualitative approach was undertaken to explain the relation between the intervention 
and the perceived effects by the participants. 
3.2 Study area 
This study was done at eleven public primary health clinics in four regions of 
Tanzania namely Tanga, Lindi, Mtwara and Pwani. The regions were selected based 
on geographical location criteria and that they had implementing point of care service 
for CD4 testing in not less than a year.. The sites were selected from a range of 
settings: - accessible by road, patient volumes of at least 50 patients per week
1
, pima 
device placed in clinics at least six months ago, rural setting, voluntary and provider 
initiated HIV tests and antiretroviral therapy services were routinely available at all 
clinics. Currently, the overwhelming majority of Pima devices have been placed in 
rural sites, and the sample therefore is rural-based. 
3.3 Study Period 
The study was conducted from October 10th through November 10th 2012 from 11 
public primary health clinics. During clinic visits, the data was collected from May to 
                                                        
1
 Not all clinics met these criteria.  
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September 2012 following the placement of the Pima device and the pre intervention 
data was retrospectively collected for the same period in 2011. This was purposely 
done so that there would be minimum effects of season or other confounders. 
3.4 Study Participants 
The research population included patients older than five years who were newly 
diagnosed and found to be positive during the period of study. Health care workers 
were also purposively selected based on criteria that they attended Pima training and 
were operating the device. The staffs were mainly from the laboratory and CTC. 
3.4.1 Inclusion criteria 
 HIV newly diagnosis 
 HIV positive older than 5 years old 
 Trained health care providers 
3.4.2 Exclusion criteria 
 Patients whose records were transfer to another facility 
 Patients under five years old 
 Untrained staff on Pima and all supervisors who are not directly related to 
Pima 
3.5 Sample size 
The study aimed to estimate the difference in proportions between two independent 
populations, that is, to estimate the risk difference. The formula used to determine 
sample size in each comparison group was as follows:-  
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Where n, is the sample size required in each group, (i=1, 2), z is the value from the 
standard normal distribution reflecting the confidence level that will be used (e.g. 
z=1.96 for 95%), E is the desired margin error in which the 95% confidence interval 
for difference in proportions has a margin error of no more than 0.05 or 5%. P1 and 
P2 are the proportions of success in each comparison group. In this study the 
researcher used national adult HIV incidence rate which is 0.7 as a P1 & P2. The 
calculated required sample size was 645. As a precaution the sample size was 
increased by 20%. This gave the total sample size of 806. Based on this sample size 
50% was allocated to pre Pima and 50% to post Pima introduction. Thus 403 patients 
were enrolled when Pima was not available and another 403 when Pima was available. 
3.6 Data Collection tools 
3.6.1 Quantitative data collection 
For quantitative approach a structured questionnaire was used to extract patient level 
clinical data from medical records. Simultaneously a checklist was used to collect 
observational data.  
3.6.2 Qualitative data collection 
For qualitative approach in-depth interviews were done (see interview guide in 
appendix 1.4) for health care workers. A total of 22 in-depth interviews were 
conducted involving health workers and 55 study participants (unstructured). After 
these interviews the researchers noted that additional information would not result 
into new valuable information. The selection of the clients was based on convenient 
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sampling for those who were available at the clinic upon the visit of the researcher 
and the clinics providers were purposeful selected based on the fact that they had 
been trained and were operating Pima at the clinics. The researcher chose this type of 
sampling because it was difficult to arrange appointments beforehand, and as a 
majority of the health workers and patients did not have telephones, e-mail or other 
ways of being contacted. A problem encountered at two of the selected sites using 
this type of sampling was that there was only one person working that day, so an in-
depth interview was not possible to conduct due to a large number of clients waiting 
to be attended to. All questionnaires were pre-tested (piloted) outside the study area. 
3.6.3 Observations 
The researcher conducted observations in addition to the in-depth interviews to 
provide a means of triangulating the data gleaned from the in-depth interviews, and to 
gain additional information that did not get in the interviews. One of the first things 
that the researcher must do when beginning fieldwork is to clarify what a role he/she 
will take on as an observer (Chambliss and Schutt 2006, 169). The researcher 
identifies the role and develops a checklist base on her role. Entering the field is a 
crucial stage in fieldwork and the researcher must therefore pay much attention and 
consideration to this stage (Chambliss and Schutt 2006, 172). The researcher was 
familiar with field environment and before going to the field the researcher meets 
with regional and district health management teams as a preparation stage.  
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3.7 Data analysis 
3.7.1 Qualitative 
The transcription of each interview was carried out within a few days after the 
interview was conducted. In the process of analyzing the data the researcher primarily 
used grounded theory, which is mainly inductive. The purpose is to generate theory 
based on the collected data (Chambliss and Schutt 2006, 218). An inductive approach 
allows themes to emerge from the collected data (Chambliss and Schutt 2006, 185). 
Through in-depth interviews and observations the researcher generated much data. In 
analysis process the researcher worked through all of the interviews and identified 
codes. Continued this process until no new codes emerged then placed these codes 
within main categories. Then discussed and analyzed each category and compared 
with the notes from observations. In the analysis process of the observation notes the 
researcher identified key themes and compared them with the information from the 
interviews. Then identified possible aberrant information to see if there were 
differences in what people said and actually did in the field. The researcher continued 
with this process until no new themes emerged.  
3.7.2 Quantitative 
Data analysis was done using excel software, mechanism was put in place to ensure 
quality control. Descriptive statistics such as means, standard deviation and 
proportions were calculated. Frequency tables and charts were generalized for 
relevant variables. All extracted data were dissociated from personal identifiers and 
remained anonymous and unlinked throughout the study.  
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3.8 Validity and reliability 
At the end of each day all the forms were reviewed by the interviewer and mistakes 
were immediately corrected.  
3.9 Ethical consideration 
The researcher is affiliated with both the Ritsumeikan Research Centre for Asia 
Pacific Studies (RCAPS) and Tanzania National Institute for Medical Research 
(NIMR). The letter of approval from RCAPS and research proposal was submitted to 
Tanzania’s NIMR for approval. Also the partner organization Clinton Health Access 
Initiative in collaboration with the Ministry of Health and Social Welfare authorized 
the researcher with an introductory letter. Informed consent was obtained from each 
participant.  
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CHAPTER FOUR 
FINDING AND DISCUSSION 
4.1 Impact of Pima on HIV case management 
When Pima was not available a total number of 1105 patients were enrolled at the 11 
sites (see table 4.1). Of these 407 were selected based on inclusion criteria to meet the 
sample size. When Pima was available a total of 996 were enrolled at the 11 sites. Of 
these patients 407 were selected based on inclusion criteria. There was no difference 
in age, sex between the participants before and after the introduction of point of care 
testing as per table 4.1. 
Table 4.1: Study participants before and after the introduction of point-of care CD4 
testing at primary health clinics in Tanzania 
 Pre POC CD4 test Post- POC CD4 test 
All patients Enrolled 1105 996 
Kabuku 102 96 
Kisiju 96 112 
Kitomanga 92 86 
Mahuta 98 72 
Mchichira 106 103 
Mkamba 96 96 
Mkuzi 109 98 
Mwera 94 86 
Nanyamba 105 83 
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Rutamba 95 76 
Nanguruwe 112 88 
      
Study participants 407 407 
Kabuku 37 37 
Kisiju 37 37 
Kitomanga 37 37 
Mahuta 37 37 
Mchichira 37 37 
Mkamba 37 37 
Mkuzi 37 37 
Mwera 37 37 
Nanyamba 37 37 
Rutamba 37 37 
Nanguruwe 37 37 
Younger than 18 years of 
age 
29 33 
Female % 310 280 
 Source: Author  
4.1.1 Lost to follow before staging, between staging and ART initiation and 
between enrolment and ART initiation 
The introduction of POC CD4 testing helped to reduce lost to follow up. Total losses 
between enrolment and antiretroviral therapy initiation dropped from 90% to 73%. 
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This effect was due mainly to a reduction in loss to follow-up before completion of 
CD4 staging, which decreased from 55% to 18%. Loss to follow up between staging 
and antiretroviral therapy initiation for treatment eligible patients did not change after 
the introduction of point of care CD4 testing. 
Figure 4.1: Lost to follow before staging, between staging and ART initiation and 
between enrolment and ART initiation 
 
Source: Author 
4.1.2 The effect of point of care CD4 testing on the rate of CD4 count at 
initiation and time to antiretroviral therapy initiation 
On average, patients’ CD4 count at first CD4 test raised 24.7 cells after the 
implementation of Pima, from an average of 255.6 cells/L to 280.3 cells/L of blood. 
This can be attributed largely to HIV patients being tested closer to diagnosis, and 
therefore earlier in their disease progression. 
This study found substantial differences in timing of ART initiation before and after 
the implementation of Pima. On average, clinics saved 77 days in time between 
diagnosis and CD4 testing after the introduction of Pima testing, reducing time by 
0
100
200
300
400
500
600
700
Pre Pima
Not lost
 Pre  Pima
Lost
After Pima
not lost
After Pima
lost
Before staging
Between Staging and
ART
Between enrollement
and ART
  45 
 
86%, to 12 days from an average of nearly three months (89 days) prior to Pima 
implementation. In total, averages of 63 days were saved in time between diagnosis 
and initiation onto ART, with 22 days saved in time between eligibility for and 
initiation onto ART. Time between diagnosis and initiation onto ART fell from 88 
days to 25 days after the implementation of Pima. Time between eligibility and 
initiation fell from 33 days to 11 days.  
While the majority of clinics reduced time and increased CD4 count at initiation, 
there were outliers in each category. Clinics in this category included Rutamba, 
Kitomanga, Mwera, and Kisuju who all reduced their Time to first CD4 test by more 
than 90%. Rutamba, and Mkuzi also reduced their ART Time by more than 90%. 
Though it is hard to quantify, clinics that were judged to have consistence supply of 
Pima logistics and daily provision of Pima services reduce their times by upwards of 
80%. In some clinics, CD4 count at initiation fell after the implementation of Pima, 
which the researcher speculate may be due to a backlog of patients needing CD4 tests, 
inconsistence supply of Pima suppliers, breakdown of Pima machine and changing of 
schedule for providing Pima services from daily to once per week. Hence the disease 
status of those patients has progressed in the absence of a CD4.  
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Table 4.2: Clinical Outcomes Before and After Introduction of Pima, Site by Site 
Region 
 
Clinic 
CD4 Count at 
Initiation TAT to CD4 Test 
TAT from Eligibility 
for to Initiation on 
ART 
TAT from HIV Diagnosis to 
ART Initiation 
Before After Before After Before After Before After 
Mtwara 
Nanyamba 158.50 0 0 0 23.08 3.00 117.00 28.47 
Nanguwere 356.60 233.91 0 0 38.25 20.75 55.75 55.38 
Mchichira 402.00 356.67 0 0 30.50 13.33 84.50 13.33 
Mahuta 119.875 126.88 0 0 33.44 1.33 100.44 25.89 
Lindi 
Rutamba 303.75 425.33 31.86 0.86 4.00 0.00 30.00 0.00 
Kitomanga 183.56 257.29 108.67 11.38 28.67 23.00 197.44 27.29 
Tanga 
Mwera 161.50 263.36 21.00 2.09 26.50 9.75 45.75 12.00 
Mkuzi 150.33 328.60 63.50 22.30 102.33 4.20 112.00 23.57 
Kisuju 375.56 278.09 145.50 3.91 47.25 18.38 58.40 20.63 
Pwani 
Mkamba 187.78 236.60 233.22 40.00 26.56 18.43 149.00 55.29 
Kabuku 412.25 296.20 15.75 3.10 4.00 5.40 13.00 10.60 
Source: Author
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       Table 4.3: Clinical Outcomes before and after Introduction of Pima, Averages (Source: Author) 
Indicator Before After % Change 
Pre- Initiation 
CD4 Count at First Test 255.61 280.29 19.39% 
Time between diagnosis  to  
first CD4 test 88.50 11.95 -86.04% 
Post- Initiation Time between staging to 
ART initiation 33.14 10.69 -56.42% 
Time between Diagnosis to 
Initiation 87.57 24.77 -65.43% 
 Figure 4.2: Time between diagnosis and first CD4 test before and after Pima (Source: Author) 
 
 
           
2
                                                        
2
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Figure 4.3: Time between eligibility for and initiation onto ART 
 
Source: Author 
4.1.3 Impact of Point of care on patient schedule to receive CD4 testing 
Before the introduction of Pima, clinics had scheduled patients for CD4 testing twice per 
month while some once per month. After the introduction of Pima there was a drastic change 
in this schedule. There was still a fair amount of variation. Almost 50% of the clinics had 
testing available throughout the week including weekends. While another 50% followed the 
clinics days’ timetable of testing twice per week which resulted into attrition. This finding 
raises major concerns. 
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Figure 4.4: CD4 Testing as a share of need, before Pima (Source: Author) 
 
Source: Author 
Figure 4.5: CD4 Testing as a share of need, After Pima (Source: Author) 
 
Source: Author 
On average, clinics reduced the number of patients turned away each week by 50.98%, from 
76.24% to 25.26%. Weekly CD4 testing need was calculated based on the number of active 
pre-ART and ART-initiated patients, and WHO testing guidelines. Some clinics exceeded the 
projected weekly need, as seen on the graphs below. These clinics may have a CD4 testing 
backlog from sample transport or other logistical challenges. Though clinics expanded CD4 
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testing, after Pima implementation, on average, clinics still only met 74.76% of CD4 testing 
need. This may be due to insufficient patient demand or loss to follow up due to capacity 
limit (use of previous system of scheduling the patient and devise challenges such as stock 
out and breakdown).  
Also clinics increased the volume of patients tested per month by an average of 244.71% over 
their pre-Pima volumes. The specific results can be seen below.  
Table 4.4: Average patients tested per month 
 
Pts who 
need 
testing per 
month 
Avg pts 
tested per 
month, pre-
Pima 
 
Total pts 
tested in 
sample 
period 
(2011) 
Avg pts 
tested per 
month, post 
Pima 
Total pts 
tested in 
sample 
period 
(2012) 
Increase in % of 
patients tested 
Kabuku 133.08 37.80 
 
189 59.80 
 
299 58.20% 
Kisuju 54.46 2.00 
 
10 24.00 
 
120 1100.00% 
Kitomanga 45.54 5.60 
 
28 62.60 
 
313 1017.86% 
Mahuta 118.15 14.00 
 
70 17.40 
 
87 24.29% 
Mchichira 4.00 0.00 
 
0 5.60 
 
28 100.00% 
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Mkamba 23.08 0.00 
 
0 40.60 
 
203 100.00% 
Mkuzi 38.62 40.00 
 
0 30.80 
 
154 -23.00% 
Mwera 27.38 6.20 
 
31 20.00 
 
100 222.58% 
Nanguwere 56.77 12.60 
 
63 13.20 
 
66 4.76% 
Nanyamba 82.92 13.80 
 
39 15.40 
 
77 11.59% 
Rutamba 44.92 18.00 
 
90 31.60 
 
158 75.56% 
Source: Author 
 
4.1.4 Effect of Point of care on waiting time 
When Pima is available the standard waiting time should be 20-30 minutes. Before Pima 
introduced the interview with the staff revealed that testing was done twice per month and 
patients had to wait almost more than 8 weeks to get their results. This scenario changed, 
after Pima, results were now returned in 30 minutes in most cases. There were instances 
when for some social reasons patients left immediately after blood collection, in this case the 
delay in giving the feedback was less than 24 hours. Additionally due to increase volume of 
patients there were instances results were given the next day. Overall the waiting time after 
Pima did not exceed 24 hours. 
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4.1.5 Impact of POC CD4 testing on gender 
 
The number of women tested is more than 60% higher than men; this may be due to higher 
number of Tanzania women with HIV than their male counterparts (MoHSW, 2007, 2). 
Health workers and clients we spoke with at the facilities reported that positive male 
involvement was an important motivating factor for participation in the different services. At 
the majority of sites we visited, there were low rates of male participation in the CD4 testing 
programs, while other facilities had a higher number of men participating. We questioned 
health workers at the sites with high male involvement regarding what had made the 
difference in motivating men to participate in the services. According to these interviewees, 
the most important factor motivating men to participate in the services was previous 
education and information, and understanding regarding the program among men. Suzan said, 
“Men that get proper education come for testing”. The interviewees emphasized that the men 
needed information and motivation specifically aimed at men, such as books, brochures and 
art groups. Some health workers at facilities that had previously educated men when they 
visited the facilities believed that these men passed the learned information on when they met 
other men in the streets. However, most of the health education was given at the facilities, 
and as previously discussed; most men did not regularly visit the facilities so reaching these 
men with health information constituted a challenge. 
Other possible reasons for low male involvement in HIV related services. Health workers at 
one hospital told us that only a few men came in for HIV testing because they feared that it 
may take much time and they could not afford to lose a day of work. While others said that 
few men knew their HIV status because they did not understand why they had to go for 
testing. Several others told us that some men believed that they would have the same results 
of an HIV test as their wives and therefore felt that they did not need to be tested themselves. 
One interviewee indicated that men sometimes refused to accept the results of a positive 
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HIV test. Neha was of the opinion that men did not come for testing because they were 
afraid: “They [the men] are mainly afraid because they have many partners.” 
The interviewees described initiating different types of interventions in order to attract 
men and encourage them to be more involved in the HIV related services. The health care 
workers told that most of the women were told to bring their husbands; some were 
providing an invitation letter. 
When we asked clients and community members about suggestions how to effectively reach 
more men, some people mentioned going from home to home providing education and 
information, while others suggested the use of mobile services (services that are offered 
outside the health facilities, e.g., in the villages or in people's homes). Benjamin expressed 
his suggestions as: “Men need motivation. Women that go to the clinic should motivate them 
to go. Also NGOs and nurses should motivate men to go. They should go from house to 
house and teach the men about the importance. 
4.2 Barriers to the implementation of Pima 
4.2.1 Delay due to Chemistry and Haematology test 
Clinicians reported that though POC CD4 testing relieved some delays in ART initiation, a 
bottleneck remained due to the need for laboratory-based baseline testing. For initiation of 
ARVs, three sets of laboratory results are mandatory i.e. CD4, Creatinine and hemoglobin. In 
the study site only 1 Health centre namely Rutamba had Point of Care for both CD4, 
Creatinine and Hemoglobin test and the results were available and treatment was initiated 
timely. In other site point of care for creatinine test were not available, they are relying on 
sample transportation thus treatment initiation was delayed. Clinicians who want to order  
cretinine test faced with challenges of not only transporting the blood specimen to and off site 
laboratory but also getting the result back to the patient. They had many additional challenges 
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such as blood specimen being damaged or unsuitable for testing as the result of delays in 
sample reaching to the district laboratory, losing of the result due to unclear system. Patients 
are often lost due to repeated visits to the health facilities as well as delays in returning results 
Hence 90% of the clinics initiated ARVs without laboratory result for creatinine. This finding 
raises major concerns. 
Figure 4.6: Total testing volumes across all sites, before the introduction of Pima (Source: 
Author) 
 
Figure 4.7: Total testing volumes across all sites, after the introduction of Pima (Source: 
Author) 
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4.2.2 Staff Shortage 
A majority of the clinicians and clients reported staff shortage as a big problem, as Bakari 
clearly expressed, “Shortage of staff is a problem, an important problem.” Many of the 
facilities we visited only had a few health workers employed. The study observe shortage of 
staff in term of numbers and skills, more than 90% of the clinic visited does not have 
laboratory technician. Laboratory assistants who are available are medical attendants who 
were recruited through on-the-job training. The health workers were supposed to complete 
many different tasks such as providing different services, providing health education, 
attending follow-up appointments at the patient’s homes, cleaning the facility and fetching 
water. As Zuwena stated, “We need more staff, so we can be able to follow-up the patients. 
There is a nurse assistant here, but she can’t do follow ups because of other activities.” Some 
facilities had expert patients or volunteers helping, but most health workers said that there 
were too few volunteers and community health care providers to do follow-ups of patients 
and provide health education. Some facilities we visited had long lines of people waiting 
outside and only one or two health workers present. As Anna stated, “We are only three 
health workers and lots of patients, so they have to wait a long time to get the services.” 
People we spoke with reported that some people faced problems spending so much time 
waiting at the facility, as they had various tasks waiting at home. Most people reported that 
they were paid per day’s work, and that many could not afford to go to the facility when it 
was so time consuming. Many of the health workers we interviewed indicated that they were 
unmotivated because they often had to work overtime with no compensation. One female 
health worker at a health centre, Silvia, said that she sometimes worked for three days 
straight without any time to rest or sleep, and with no overtime payment. They emphasized 
that with such a shortage of staff their working conditions were arduous and they became 
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tired of having to bear so much responsibility alone. Mohamad said that poor management of 
health workers was also a problem which was caused by shortage of staff and that they often 
did not have the chance to follow up with workers. Through conversations and interviews 
with these health workers and through our observations of their work, the study found that 
none of the health workers talked to were pleased with his/her job situation.  
4.2.3 Distance and transportation 
The visited regions are expansive and many people live far from the health facilities. The 
study found that the clinics visited are not offering mobile clinic services due to lack of 
transport. At some facilities, results from CD4 tests took some time before they were ready. 
This meant that the persons tested had to come back to the facility another day to get the 
result. In such case the time aspect can be a challenge, as people reported that this long 
waiting period was a reason patients sometimes did not return to the facility to receive the 
result for their CD4 test. The study also found that some of the health care workers are 
sending patients away for non-same day testing. Hence the need to visit the facility several 
times was frequently mentioned as a barrier, and the different obstacles to accessing the 
facilities may lead to discontinuance of services when extra visits are required. 
However, the study found that only a few areas had available buses, and only a minority of 
people had available vehicles, including bicycles. To access the health facilities most 
people’s only option was to walk. Lack of transportation and far distances were two 
important factors that may have affected the decision to use Pima services. The study found 
that spending such amounts of time in accessing the facilities created other challenges in a 
client’s everyday life including what to do with the children, the possibility of losing a day of 
work and income, and the fact that many people had other tasks they needed to prioritize at 
home. Some emphasized that transportation was especially difficult in the rainy season when 
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the roads flood and become difficult to travel on. Mwajuma explained a consequence of this 
reality: “In the rainy season, they are not affording to go to the facility. For the facilities 
which are not offered creatinine testing patients were referred to other facilities which were 
farther away; this could have been a potential factor for why they did go for testing. A few 
health workers said that they had cars available for transport, and stated the offered 
transportation services acted as a motivating factor for patients. Several health workers, 
however, expressed a need for means of transportation for mobile clinics. Some of the 
facilities that had available vehicles reported frequent lack of funding for fuel and 
maintenance of the vehicle. The study observes an example for this: a facility had been 
provided with several motorbikes in order to reach out to patients in need, however, these 
were not in use due to the lack of funding for maintenance and fuel.  
As distance could be a hindrance to seeking services for those who lived far from their local 
health facility, living within close proximity of the facility was reported as a motivating 
factor to use the services provided. As one female dispensary health worker, Naomi, 
suggested, “Most people who use the clinic live close to it. Also health care workers are 
unable to follow patients due to workload at the clinic, distance and lack of the transport, so 
most of clients who lost to follow when Pima was not available have not been traced and 
returned back to the facilities for continuation of services.  
4.2.4 Lack of space 
The researcher observed and was informed by different people that for a majority of facilities, 
lack of space for privacy were a problem. Paul stated, “It is hard to give the services privately 
because of lack of space.” The study found that some facilities did not have a separate room 
for testing or for giving test results. Some of the people reported that the lack of privacy made 
the facility undesirable for seeking services. From observation the researcher discovered that 
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CD4 testing at the point of care created a risk of involuntary disclosure due to the lack of 
privacy space. Interventions that contributed to privacy was said to motivate the uptake of 
services. As we continue to introduce new point of care devices we should also think of 
multifunction devices to reduce space.  
4.2.5 Training and Skill 
The initial training from Both Region was held by the Trainers of Trainees from the Ministry 
of Health and Social welfare, CHAI and RHMT at their regions. One of their trainers noted a 
lot of variation between what the participants knew from before. Some were fast, some had 
inquiries. The training was aimed to a specific department; about 2 people from each clinic 
were trained one from Care and Treatment clinic and the other one from Laboratory. 
According to the trainer this was done to ensure the device can be operated by both lab and 
CTC staff to avoid long cure, 80% of the trained staff are operating the device but when they 
are not around the device are operated by other staff who have been learn from trained staff. 
Trainers generally reported that they were satisfied with the content and amount of training, 
but error reports, failure to order Pima suppliers, unclear with the plan preventive 
maintenance issues, poor recording of CD4 logbook and unclear information about Pima 
revealed that many providers did not achieve the training objective and hence incorrectly 
using of Pima device. See Appendix 1.4 for complete description of training protocol from 
National Implementation Plan for POC CD4 Testing. 
4.2.6 Use of Pima 
Most of the health staffs that are using Pima are medical attendants. At each clinic, error 
reports and testing volumes were extracted from the Pima device using a USB stick. From 
this information, the researcher was able to assess the frequency and types of errors. On 
average, 21.5% of Pima tests performed had an error. The clinic with the highest error rate 
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had errors in 40% of tests performed. The best performing clinic had errors in only 2% of 
tests. 50% of errors occurred in May, the month after Pima placement. The next-highest 
months for errors were August and September, with 16.77% of errors in each. Some clinics 
experienced a stock out of controls and reagents in August and September; the lower error 
rates in these months may be due to lower testing volumes, rather than improvement in 
operator skills. Among the error occurred in August and September, error rate was 6.5 among 
sites that used venous blood, 5.5 among sites that alternate between finger prick and venous 
blood and 4.8 among sites that use finger prick blood sample. 
4.2.7 Supply Chain Management 
Of the eleven sites visited, six reported stock challenges, and four additional sites reported 
stock outs of Pima supplies (controls and reagents). None of the sites visited were able to 
show us ordering forms for Pima supplies; most of the clinics had supplies delivered to them 
(“push system”) from the regional or district hospital, Medical Department store or local 
partners.  The pushing system has disadvantages as the facility are receiving the supplier’s 
which are not of their choice and in less or additional amount. In Tanga Region the Medical 
Department Store (MSD) supply Pima supplies through pushing system and they end up 
supplying to the sites which they don’t have Pima machine. 90% of the clinics are using the 
old form for request and ordering (R&R) which did not integrate Pima suppliers. 
Logistics/supply chain was a challenge at 100% of facilities- all facilities had either not 
placed an order for reagent or placed an order that went unfulfilled. Need to improve the 
communication capabilities between facilities and districts authority and MSD for reliable 
supply chain. 
  60 
 
4.2.8 Electricity supply (inconsistent electrical and mechanical services) 
Of the clinics surveyed, eight relied on solar power, and reported rainy season outages that 
constrained testing capacity. The remaining clinics (Mahuta, Mkuzi, and Kabuka) had access 
to grid power, and reported power rationing. Among 11 sites 8 sites reported having problem 
with Pima battery, it does not last long and breakdown of the machine. 
4.2.9 Security 
Security is poor in the entire clinic visited that why most of Pima machine are located in the 
laboratory and not at the entry point like VCT, PMTCT and CTC due to lack of security. The 
study observes poor security in most of the entry point such not having doors, windows, locks 
etc. In future these things needs to be taken into account as they will assist to have a good 
patient flow and reduced lost follow up between diagnosis and enrolment.  
4.2.10 Cost effectiveness 
As we are providing Point of Care for CD4 testing, cost control is very important for 
efficiency delivery of the services. Current the implementation is not cost effective due to the 
fact that the clinics needs high control and supervisions, they are not able to manage on their 
own, frequently supervision and mentoring is needed for capacity building, the devices has 
been placed in the clinics with low patients volume although one of the criteria for 
implementation was to the sites with high patients volume, therefore sample ratio is small 
which makes them to have unused expired suppliers. Though clinics expanded CD4 testing, 
after Pima implementation, on average, clinics still only met 74.76% of CD4 testing need. 
This limited opportunity for economic of scale due to fixed test volumes per unit of 
infrastructure and staff.  
 
  61 
 
Other findings 
i. More factors impact Pima utilization and the impact on CD4 access than just patient 
volumes. 
ii. Clinics days: Facilities with more than 2 clinic days per week increase testing rate 
than those with one or two clinic days. 
iii. Facility leadership: having strong leadership improve documentation rate over 90% 
also the Pima training help to improve documentation by more than 80%. 
iv. The facilities using finger prick increases testing rate while those using venous blood 
decrease by 5%. 
v. Documentation of the CD4 result improved when compares with the period before the 
introduction of Pima as their documentation were very poor with incorrect and 
incomplete filling of the logbook and most of the clinics they were not available. 
vi. 80% of the facilities using venous blood with limited of the same day results which 
eliminating the point of care advantage. 
vii. Utilization of the machine within was differ from one site to another due to machine 
breakdown, scheduling of patients, inconsistence of power supply and inconsistence 
supply of Pima supplies. 
viii. Supervision, feedback and support to the health facilities. 
ix. In some facilities the study found poor communication and coordination among entry 
points. 
x. Most of the facilities we found that they run control but the program do not monitor 
the quality of the clinic with high testing rate. 
xi. The program needs training of many operators due to high staff turnover. 
xii. In general staffs are committed as 80% of the trained staffs are operating the device. 
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Contextual Observations 
There were many factors that influenced the use of the Pima in Tanzania, and impacted the 
results of the study. Successful use of the Pima device and effective implementation relies 
upon well-trained nurses and clinicians, timely delivery of supplies, reliable power and 
infrastructure, and leadership from local authorities. Below are some observations on how 
these factors interacted and the impact they had upon findings.  
 Category Issue Impact 
In
fr
as
tr
u
ct
u
re
 
Facility 
Infrastructure 
 
Power sources and reliability were not 
assessed prior to the placement of a Pima 
device.  
Long testing outages due to power instability were 
common, with several clinics reporting outages of one 
month or more due to power.
3
 
Human 
Resources 
Only 2 clinicians were trained per site; 
all others trained through on job training  
Staff shortage and turnover, majority who are working has 
been trained through on job training, leads to 
miscommunication about the correct use of Pima device. 
High error rates (up to 40%) resulted.  
C
o
m
m
u
n
ic
at
io
n
 
District Level Inconsistent messaging from district 
officials and local partners on the correct 
use of Pima, and the accuracy of the 
device and lack of support from regional 
and district authority  
One clinic reported that the DMO felt the Pima results 
were inaccurate, and told the clinic not to use these results 
for clinical decision-making.  
Many other clinics reported confusion over whether to use 
finger sticks or venous blood draws and patient 
scheduling.  
S
u
p
p
ly
 C
h
ai
n
 M
g
m
t 
PIMA—
cartridge 
Ordering 
Inconsistent or incorrect ordering of 
supplies including reagents, cartridges, 
and finger stick kits. Many clinics had 
never ordered supplies, and did not know 
how. 
Many clinics stocked out of Pima supplies as soon as their 
initial supplies ran out, usually in July or August. Some 
clinics had never re-stocked after the initial supplies ran 
out, and therefore had only used their Pima device for 6 
weeks. Currently they are using pushing system to receive 
the suppliers. 
                                                        
3
 Though solar chargers are available for the Pima device, none of the clinics we visited reported receiving one.  
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 Category Issue Impact 
PIMA—
cartridge 
delivery 
Push system from district to clinics Clinics reliant on local officials to deliver supplies. Delays 
at district or regional level led to stock outs.  
Forecasting Clinics do not order their own supplies 
and do not forecast their need based on 
consumption. 
Testing volumes fluctuated highly from month to month 
due to availability of supplies, and clinics did not correctly 
assess their consumption. Stock outs resulted at four 
clinics; with six others reporting stock challenges for Pima 
supplies.  
T
es
ti
n
g
 P
ro
ce
d
u
re
s 
Sample 
Transport 
Many clinics profited from the sample 
transport system. 
Some clinics maintained the sample transport system and 
continued to send CD4 samples to the district hospitals 
after the placement of Pima devices.  
Chemistry Tests Many clinics were not performing any 
chemistry or hematology testing. 
Patients are not being properly monitored for side effects 
of ART medications.   
POC 
Hematology 
 
 
 
 
PPM 
Stock outs and power failures prevented 
POC Hb (Hemocue) machines from 
functioning effectively.  
 
 
Staff do not have any clue regarding the 
plan preventive maintenance, when they 
had a breakdown they are just staying 
with the machine without taking any 
action 
Patients are not receiving Hb tests prior to initiation on 
ART.  
 
 
 
 
 
Services are not provided and patient are turned away for 
next visit 
Source: Author 
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4.3 Discussion of Research Findings: 
4.3.1 Patient retention 
The overall evaluation of Pima introduction in the study sites reveals a positive contribution. 
This study shows that the positive impact of Pima is related to many factors. The study found 
positive impact on attrition rate. The proportion of patients lost to follow-up before 
completion of CD4 staging decreased from 55% to 18%. Total losses between enrolment and 
antiretroviral therapy initiation dropped from 90% to 73%. Time between diagnosis and 
initiation onto ART fell from 88 days to 25 days the improvement may be due to the 
reduction of time taken to stage patient from nearly 3 month to 12 days, which reduce the 
opportunities for lost to follow up and increase the number of treatment eligible patients who 
progressed to treatment. Similar outcome were shown Jani et al. (2011) that after the 
introduction of POC CD4 testing the proportion of patients loss to follow up before 
completion of CD4 dropped from 57% to 21% and loss to follow up before initiation of 
ARVs fell from 64% to 33% and the proportion of patients initiating ART increased from 
12% to 22%. The median time from enrolment to antiretroviral therapy initiation reduced 
from 48 days to 20 days primarily because of reduction in the median time taken to complete 
CD4 staging, which decreased from 32 days to 3.Lost to follow up between staging and ART 
initiation did not change this may due lack of laboratory-based baseline testing for creatinine 
and hemoglobin. It may also be due to lack of transport or time to visit the clinic to attend 3 
ART counselling session before initiation. Further research is needed to investigate the cause.  
4.3.2 Time to initiate ARVs and CD4 counts closer to 350 
This study also demonstrates a two way benefit- the substantial differences in timing of ART 
initiation before and after the implementation of Pima and proves that POC CD4 testing 
enable more patients to initiate ART with cell counts closer to 350. This can be attributed 
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largely to HIV patients being tested closer to diagnosis, and therefore earlier in their disease 
progression. Current WHO ART guidelines recommend initiation onto ART for all patients 
with a CD4 cell count at or below 350 cells per μL. However, a recent review of eight sub-
Saharan African countries found that median CD4 cell count at initiation was 136 cells per 
μL (Nash et al. 2011). POC CD4 testing may enable more patients to initiate ART with cell 
counts closer to 350 by increasing the number of patients who are successfully staged, and by 
decreasing LTFU prior to initiation onto ART (Jani et al. 2011). Constrained access to CD4 
testing results in late initiation onto ART, which imposes costs on patients including 
additional morbidity and mortality, and poor treatment prognosis once initiated onto ART 
(Larson et al. 2010). Studies have shown that a low CD4 count (<100 cells/ μl) at initiation is 
a major predictor of HIV/AIDS mortality (Lawn et al. 2009& Lawn, et al. 2008). Immune 
system recovery after 3 years on ART is also positively correlated with a patient’s CD4 cell 
count at initiation (Robbins et al. 2007). 
4.3.3 Convenience and easiness to get tested 
The questionnaire part of the study revealed that patients now had more satisfaction in terms 
of convenience and easiness to get tested. The same sentiments were expressed by health 
workers. Similar outcomes were shown by Zachariah R S. (2011) that POC CD4 testing 
remains a vital entry door to accessing ART, improving immediate decision making, patient 
management and referral, reduced visits, waiting time for patients and accessible to the rural 
community. This study also found that POC CD4 testing reduced waiting time and visits for 
patients. The expansion of POC testing therefore help to overcome logistical and geographic 
barriers to full-scale roll out of HIV treatment and care, increasing the number of patients on 
ART and reducing HIV-related morbidity and mortality.  
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4.3.4 Facilities Infrastructure 
This study also reflects issues about infrastructure. The results indicate that a supportive 
infrastructure is very essential for Pima testing these supportive infrastructures include other 
support test like cretinine and hemoglobin, staff, sufficient training, reliable supply chain, 
quality assurance, space, and security, consistent electrical and mechanical service. Similar 
findings were shown by Peter T et al. (2008) that in planning to implement point of care 
services its crucial to consider some of the challenges the program might face especial in the 
rural clinics such as shortage of staffs, uncommitted staff, lack of space, security, inconsistent 
electrical and mechanical service, poor communication system, poor documentation of 
medical records, unreliable supply chain, high risk of unused expired supplies, fixed test 
volumes per unit of infrastructure and staff, training of many operator due to staff turnover 
and monitor of quality at clinics with high testing rate. Many of this challenges can be solved 
with a good strategy of implementation.Though significant improvements in clinical 
outcomes were observed after the introduction of the Pima device in Tanzania, these 
improvements were mitigated by implementation challenges including human resource 
shortages, inconsistent power, inconsistent supplies, insufficient knowledge on the use and 
maintenance of the Pima, and incorrect use of the device. Patient flow, or a good workflow is 
been control by the location of Pima machine. Currently most of the machines are located at 
the laboratories for security issues with few located at CTC. Most of the laboratories visited 
are far from the entry point and the patient had to cue for services. Having Pima machine at 
the entry point like VCT, CTC or PMTCT will maximize utilization of Pima device and 
reduce lost to follow up between diagnosis and enrolment which is also high in Tanzania. 
Serious supply chain issues exist at the clinic level. There was a generally poor understanding 
of the ordering process for obtaining new reagents and cartridges for the Pima device, with 
many clinics reporting that they had never placed an order for Pima supplies. Also the study 
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found that there is serious shortage of ARV drugs and ceprin. The study from Northern 
Tanzania found that the health facilities often lacked basic equipment and medication 
(Plummer et al. 2006, 463). Harms et al. (2005, 263), found that together with fear, the most 
frequently reported cause for not taking HIV tests was lack of treatment, both for men and 
women. Other studies have also found a serious shortage of drugs for different purposes 
(Mrisho et al. 2008, 674-675; Schellenberg et al. 2008). 
4.3.5 Sub optimal utilization of Pima 
The observation part of the study showed that several clinics are using the Pima in a way that 
does not take full advantage of the benefits of POC CD4 testing, including sending patients 
away for non-same day testing and using venous blood draws. Most of the facilities visited 
are not capable of using finger-prick blood sample. According to Pima SOP test operators 
should be trained on both venous blood and finger-prick blood sample collection, as both are 
viable options for POC CD4 testing and may be appropriate under different circumstances. 
Proper training on sample collection of both venous and finger prick blood sample resulted to 
reliability of CD4 count by Pima, this will also reduced errors identified. Adequate training 
for correct use of finger prick blood sample is highly needed for proper collection of finger 
prick to avoid multiple pricks (Herbert et al, 2012; Mtapuri Zinyowera et al, 2010; Kafufu 
Fred, 2010). Without the improvement of finger prick blood collection the reliability of the 
CD4 count by Pima analyzer is questionable (Thakar et al, 2012). Pima performance is highly 
correlated when using venous blood but if the finger prick blood sample are correctly 
collected and tested there is also high correlated (Glencross et al., 2012). In this study high 
rate of error observed in clinics used venous blood rather than finder pricks which means the 
perfomance depend on capability of staff in collecting both venous and finger prick blood 
sample. 
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4.3.6 Health worker constraints 
Also the observation part of the study showed that most of clinics the device are operated by 
Laboratory attendant or nurse assistant who has been train through on job training by other 
staff. This situation is due to staff shortage in term of number and skills including staff 
turnover. According to Pima SOP in the event that a test operator is transferred to another 
facility and a new operator needs to be trained, this training should be conducted only by 
official trainers who have received the TOT module from the supplier, rather than one 
operator training another. Studies from southern Tanzania found that staff shortage was 
common in this area (Schellenberg et al 2008; Mrisho et al. 2009. Simba et al. (2010, 25) 
state in their article, that Tanzania had a staff gap of 33% in the health workforce. The study 
showed variation in the staff workload among health providers at various facilities. The 
workload at hospitals was lower than the workload for health providers in primary health care 
facilities. This study also experienced shortage of staff at several of the facilities visited. 
Almost all interviewees stated that they needed more human resources to be able to take care 
of all the patients, in addition to all the different tasks they had at the facility. We found that 
staff shortages created challenges in several ways: not having enough people to attend to all 
the patients that were in need of services; not having enough trained staff led to decreased 
quality of the services; the shortage of staff created a pressure for the existing health workers 
due to higher workload; and health workers felt unmotivated. As in accordance with the 
broader literature, many of the health workers reported a lack of motivation in their work. 
The reasons given for these feelings included overtime hours without compensation, feeling 
too much responsibility and not enjoying their work. As there were many facilities with only 
a few health workers employed, most facilities had massive amounts of work to complete 
each day. As most of the Lindi region is rural area, the majority of health workers lived close 
to the facility where they work, and many of them were on duty 24 hours per day. As other 
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studies also found, our data indicate that these feelings of discomfort and unhappiness could 
have had a negative impact upon their performance as health workers.  
4.3.7 Mobile clinics (outreach) 
The questionnaire part of the study revealed that clinics are not conducting outreach/ mobile 
clinics to the nearby community or clinic without Pima due to lack of transport and funding 
for fuel. Some of the clinics that had available vehicles reported frequent lack of funding for 
fuel and maintenance of the vehicle. The study observes an example for this: a facility had 
been provided with several motorbikes in order to reach out to patients in need, however, 
these were not in use due to the lack of funding for maintenance and fuel. Currently clinic 
with Pima act as point of referral which limit the coverage and uptake. 
Several previous studies have explored distance from the health facility as a barrier for uptake 
of health services (Myer and Harrison 2003, 268-270; Van Eijk et al. 2006; Mrisho et al. 
2007, 863+870; Schellenberg et al. 2008, Creek et al. 2009, 357; Mrisho et al. 2009). 
Additionally, lack of reliable transport is described in other studies from the area as a 
problem (Mrisho et al. 2008, 675). (Mrisho et al 2007, 863) write that distance and 
transportation were two factors affecting the decision to go to the health facility. 
(Schellenberg et al. 2008) investigated both of these aspects and found that large distances 
and lack of transport was difficult in relation to referrals to other facilities. Patients reported 
there were poor infrastructure related to transport and roads in both regions long distance and 
lack of transport option was widely reported as obstacles for accessing health facilities. This 
clearly challenges uptake of CD4 testing. Most of the health workers spoke with said that the 
majority of people had to access the facilities by using bicycles or on foot, which underlines 
the impact of distance on the uptake of CD4 testing. Focus on mobile clinic is very crucial. 
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4.4 Study Limitation 
These study findings are limited by poor record keeping at the clinic level, especially in the 
comparison (pre-Pima) period. Few clinics kept official/standard records of sample transport, 
CD4 tests, or chemistry tests.
4
 Due to inconsistent record keeping at the clinic level, it was 
often difficult to follow a single patient through the treatment process for HIV. Patients 
identified at diagnosis often cannot be tracked through baseline CD4 tests, monitoring, and 
initiation onto ART. In other cases, patients could be tracked, but the records were not 
comprehensive. As in many resource-constrained settings, data availability and accuracy was 
poor. The study focuses on an area that is mainly rural, and impact of point of care CD4 
testing in a more urban setting could turn out to be different. There are many differences 
between urban and rural settings e.g. people in urban settings may have easier access to 
information, and it may also be easier to attract human resources in these areas. Additionally, 
urban settings may have better infrastructure which can contribute to better accessibility of 
health services. To minimize error records with implausible error for example impossible 
dates were either corrected in consultation with the clinic or excluded from the specific 
analyses. 
 
 
 
 
 
 
                                                        
4
 With the exception of clinics in Pwani, who kept this information in standard MOHSW testing books. Pwani 
clinics nonetheless had very haphazard record keeping, and the books were incomplete.  
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CHAPTER FIVE 
CONCLUSION AND RECOMMENDATIONS 
5.1 Summary of Findings 
The results observed during the assessment demonstrate the potential for POC CD4 testing to 
improve clinical care, case identification, and timely treatment of HIV+ and ART-eligible 
patients in Tanzania. After the introduction of Pima 50% of the clinics had testing available 
throughout the week including weekends, which reduced the number of patients turned away 
each week from 76.24% to 25.26%. The rate of patient CD4 count at initiation increased from 
an average of 255.6 cells/L to 280.3 cells/L of blood, proportion of patients lost to follow-
up before completion of CD4 staging decreased from 55% to18%. Total losses between 
enrolment and antiretroviral therapy initiation dropped from 90% to 73%. Time between 
diagnosis and initiation onto ART fell from 88 days to 25 days the improvement may be due 
to the reduction of time taken to stage patient from nearly 3 month to 12 days, increased the 
volume of patients stage per month by an average of 244.71% over their pre-Pima volumes 
and the proportion of patients initiated ART from 13% to 26%. Though significant 
improvements in clinical outcomes were observed after the introduction of the Pima device, 
these improvements were mitigated by implementation challenges including human resource 
shortages, inconsistent power supply, inconsistent supplies, insufficient knowledge on the use 
and maintenance of the Pima, and incorrect use of the device.  
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5.2 Overall conclusion 
This study shows that there are numerous clinical benefits of the Pima device. It also shows 
that the current implementation of Pima in Tanzania is deficient leading to the benefit being 
compromised.  
If a coherent strategy is developed for Pima rollout, including improved training, clear 
forecasting, provision of solar chargers, and mentoring, the Pima device can play a crucial 
role in improving HIV care and treatment in Tanzania. However, the current approach to 
implementing the Pima device has resulted in haphazard and patchy use of the Pima, with 
corresponding patient outcomes. It is important to engage local and national leaders, as well 
as partners and clinicians to devise and communicate a cohesive POC strategy moving 
forward. Support from the regional, district authorities and implementing partner is crucial 
for reliable supply chain. 
5.3 Recommendations 
Although this study shows numerous clinical benefits of the Pima device, the current 
implementation of Pima in Tanzania prevents these benefits from being fully realized. 
Therefore the devices must be deployed effectively. POC CD4 must be integrated into the 
existing health care system, with systems and policies in support of it.  
The following factors will need to be considered when deploying POC CD4 testing: 
a) Device Placement (within the clinic): Devices should be placed at strategic patient entry 
points to minimize the burden placed on patients to receive testing. These entry points 
include the CTC area, VCT area, maternity ward, and ANC clinic.  
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b) Device Placement (targeting clinics): Because POC CD4 testing provides an important 
benefit to ANC patients; clinics with high volumes of PMTCT patients should be targeted 
as high-priority areas for Pima expansion.  
c) Availability of Space and Infrastructure: The Pima device can be operated from 
anywhere with a flat surface and space to place the reagents and consumables. Pima 
devices may also be deployed in other settings, including mobile outreach for rural 
villages and bedridden patients. Clinics, which need solar chargers, e.g. those with large 
outreach areas, should be identified, and units provided.  
d) Clinic Workflow: It is important that staff at the facility understand patient flow and 
develops systems to optimize patient flow and referrals. This will inform device 
placement, balancing patient volumes with patient confidentiality.  
e) Eligible Patients for POC CD4 Testing: POC CD4 testing should be available daily for 
all HIV clients, including newly diagnosed individuals, those in the CTC clinic receiving 
routine CD4 testing to determine eligibility for ART, and those on ART receiving routine 
immunological monitoring.  
f) Human Resources: POC testing represents an increased burden of work for clinic-based 
staff. The staffing patterns and capabilities of clinics must be assessed prior to the 
placement of a Pima device, in order to ensure that the clinic will operate smoothly and 
tests will be completed on time. 
5.3.1 POC Pipeline & Multiplex POC Testing Systems 
Moving forward, POC CD4 testing should be part of a broader POC testing strategy. The 
benefits of POC testing detailed previously are particularly relevant to Tanzania, given the 
rural-based population and long travel time to district-level laboratories. These challenges 
would be largely alleviated by moving to a system with POC testing as the standard of care.  
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Currently, there is Hb, viral load, and creatinine POC tests on the market, enabling HIV 
monitoring and treatment to be conducted entirely at the clinic level. This presents an 
unprecedented opportunity to resolve existing logistical challenges and would improve 
patient care. 
The POC market is rapidly diversifying beyond the Alere Pima device. There has been an 
increasing emphasis on POC technology in the developing world, including POC viral load 
testing. In conjunction with CD4 count, viral load provides a complete picture of a patients’ 
immune response to the virus. Viral load can inform timing of ART initiation, and provides 
information on the patients’ response to ART, once therapy has begun. POC viral load testing 
should work in conjunction with, and complement, existing POC CD4 systems.  
POC CD4 testing can be incorporated as a part of broader POC strategy and the introduction 
of other POC tests.  
5.3.2 Supportive Supervision and Mentoring 
As Pima devices continue to be rolled out in Tanzania, it is vital to ensure that clinicians are 
correctly and consistently ordering Pima supplies including cartridges, reagents, and finger 
stick kits. Given our experience in the field, it is apparent that there is currently a lot of 
confusion surrounding the ordering process; the resulting delays and stock outs have caused 
serious interruptions to patient care. Emphasizing the ordering process during training, using 
of the revised R&R forms and if possible, integrating of Pima system in the existing 
supportive supervision checklist will be helpful to ensure consistent supply and provision of 
high quality services. Regional, district authorities, mentors and implementing partner should 
provide technical assistant as needed. 
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5.3.3 Testing Incentives 
Many clinics were previously profiting from the sample transport system, and are therefore 
reluctant to switch to a POC device. It is important to engage local providers and clinic 
leaders to discuss the potential for providing incentives, and clearly communicate the benefits 
of POC testing to ensure its appropriate use.  
5.3.4 Improved Training 
Given the number of errors observed in the use of Pima (>50% in some sites), it is clear that 
existing training may need to be re-evaluated, or “topped up” after several months of using 
the device. We should engage the manufacturer (Alere) as well as national and local 
authorities to devise a training curriculum that best addresses these needs. Also needs to 
assess the performance of those trained through on job training. 
5.3.5 Opt-in Placement of Devices 
It is important to consider the criteria for placing devices as Pima use is expanded in 
Tanzania. Given the lack of interest in POC testing observed at some sites (some clinics had 
never removed the device from its box), we may want to consider an opt-in (Pull) system for 
POC CD4 testing, ensuring buy-in from the clinic side. While there are ethical concerns with 
prioritizing clinician demand, this will ensure that devices are utilized. Clinics that opt-in to 
program would be invested in the use of the device, having identified their prior sample 
transport system as problematic. We can look to other countries that have implemented new 
technologies using this model.  
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5.3.6 Supply chain Management 
Though POC protocol has been developed, there is not a clearly articulated policy around the 
procurement and distribution of PIMA units and cartridges, or the training of clinicians, and 
the monitoring of results. PIMA devices do not need to be routinely serviced, and represent a 
one-time acquisition cost for the clinic. PIMA cartridges, however, need to be acquired at 
least once annually.
5
 These cartridges come in packs of 100, and are not currently a part of 
the national distribution plan. Poor ordering by clinic staff and poor communication between 
local health centres, district hospitals, and the MOHSW have resulted in delayed deliveries, 
and stock outs of cartridges at the clinic level. It is imperative to articulate responsibility for 
distribution, as well as a clear transportation plan/schedule, to ensure timely delivery of 
supplies. Potential solutions include:  
i. Partnerships with NGO partners. Orchestrate a system that piggybacks on existing 
plans by tasking partners to visit clinic sites, e.g. as part of mentoring programs, 
supportive supervision etc.  
ii. District-level distribution. The District Hospital could be given responsibility for 
transporting supplies from the hospital level to the clinics, or supplies could be 
delivered directly to them from the central stockroom on a regular schedule. This 
would establish a push system, which is already in place in some areas.  
iii. Procurement of a buffer supply. If Tanzania is to move forward with Pima rollout, 
the acquisition of a buffer supply of all testing reagents and Pima cartridges is of 
paramount importance. 
iv. Quarterly forecasting and delivery of cartridges with appropriate expiry dates. 
Regardless of the method of transportation chosen, a dedicated forecasting and 
                                                        
5
 PIMA cartridges have a 12 month shelf life 
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procurement effort will be necessary. Ensuring the timely delivery of sufficient 
supplies will prevent waste and improve efficiencies. Distribution of the revised R&R 
form and training of staff on how to use the form and mentoring is highly needed. 
Next Steps 
1. Health Systems Strengthening 
a. Human Resources. Clinics must meet HR requirements and adhere to the basic 
staffing pattern of ART clinics as set out by the MOHSW. Staff shortage and 
turnover was main concern by the clinician, it is understood that POC testing 
increases the burden on clinic-based staff. It is imperative, therefore, that HR 
allocation and shortages be addressed prior to the placement of a Pima unit at 
a given clinic. 
2. Distribution and Supervision 
a. Procurement Plan and Ownership. If POC CD4 testing becomes the standard 
of care, a sustainable plan for the procurement and financing of units and 
cartridges will be necessary. Integrating of Pima supplies into a clinic supply 
chain is necessary. 
b. Supply Chain Strengthening. Rural clinics will still face transportation 
challenges with respect to the delivery of cartridges and potential servicing of 
units. Timely delivery of cartridges is essential to minimize waste and ensure 
continuity of care at the clinic level. Utilizing the regional or district authority, 
or partner organizations to deliver these supplies will be necessary.  
3. Stock Management. It will be necessary to define and adhere to a delivery schedule 
for Pima cartridges. The timely and consistent delivery of cartridges is necessary to 
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minimize waste and ensure consistency of results at the clinic level. Training on 
forecasting is needed to all staff at the clinic. 
4. Maintenance and Backup. It will be necessary to keep several machines in a central 
location to be loaned out when units break. It will also be crucial to design and 
implement a clear “breakdown” plan to be communicated to clinics, to minimize 
downtime during breakages and maintenance.  
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APPENDICES 
Appendix 1.1: The situation in Tanzania before the implementation of point of care 
In Tanzania HIV positive individual walked for over four hours on a hot and humidity day to 
get to a comprehensive primary health clinic in the remote areas. No paved roads and the 
public transport are almost inexistent with the majority using bicycles as the means of 
transport and anyway unaffordable. When the HIV positive individual are in need of blood 
test (the enumeration of the absolute number of T helper cells commonly refers to as the CD4 
count, to make decision on whether or not they can start antiretroviral treatment (ART), or for 
monitoring of the drug results. HIV positive individual are schedule for blood collection, 
usually at the clinic level is being done once per month. A blood specimen is collected and 
sent away using any existing transport (it can be a bus, private car, bicycle or motorcycle). 
The HIV individuals are told to return 2 weeks later to get result. The health care workers in 
primary health clinics who wish to order CD4 test were faced with challenges of not only 
transporting the blood specimen to and off site laboratory but also getting the CD4 result 
back to the patient. They had many additional challenges such as blood specimen being 
damaged or unsuitable for testing as the result of delays in sample reaching the CD4 count 
laboratory, specimen damage, losing of the result due to unclear system. Machine 
malfunction as a result of poor maintenance, breakdown, shortage of staff and lack of 
reagents due to stock outs or financial constrain.  For patient getting a CD4 testing means 
repeated visits to the health facilities leading to the delays in accessing ART and lost to 
follow up due to financial constrains.  By the time the results are ready the patient is too sick 
to return to the clinic or overwhelmed due to disturbances, such individual are frequent 
impossible to find again and end up declare as a lost to follow up. This is means the previous 
CD4 technology used was inappropriate technology that was inaccessible for rural 
communities. 
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Appendix 1.2: Clinic List 
 
1. Tanga 
a. Mkuzi 
b. Mwera 
c. Kabuku 
2. Mtwara 
a. Nanyamba 
b. Nanguwere 
c. Mchichira 
d. Mahuta 
3. Lindi 
a. Rutamba 
b. Kitomanga 
4. Pwani 
a. Mkamba 
b. Kisuju 
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Appendix 1.3: Informed consent form 
 
Dear Respondent 
I am a Tanzanian student studying international cooperation policy, specializing in the field 
of Public Health Management at Ritsumeikan Asia Pacific University in Japan. As part of the 
program prerequisite for completion and award of a master’s degree, a comprehensive 
research thesis is mandatory. 
I have chosen to research on HIV Diagnostics focusing on CD4 testing as there are still 
considerable barriers to access in Tanzania. Below are set of questions which would help in 
the analysis of my research topic. I will appreciate your participation in answering these 
questions and the information provided shall be used for the sake of the academic research 
work and improve the work of Tanzania Ministry of Health and Social welfare and their 
collaborating partners. 
 
Your participation is voluntary, and you can withdraw your participation at any time.  
There will be no costs for you in participating in the research.  
Date _______________________ Place __________________________  
Printed name of participant ____________________________________  
Signature of participant _______________________________________ 
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Appendix 1.4: Data Collection Tools and Interview Guide 
 
 
 
 
NB: This questionnaire is accompanied by a Facility data collection Excel tool where answers 
can be inputted and analyzed with the tool.
 
Interviewer name:   Date: (dd/mm/yy)   
  
 
Health Facility:______ Implementing Partner: District:   
 
Facility In-Charge:___________   Contact information:    
 
Lab staff interviewed:______                       Contact information:    
 
ART staff interviewed:______                     ___  Contact information:    
 
Triage staff interviewed:______                     __  Contact information:    
 
ART Day  YES    NO 
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General Facility Information 
 
 Basic Facility Information Notes 
1 Date of ART accreditation   
|______|______| ______|  
 dd     /   mm    /    yy    . 
 
2 Rural/Urban  Rural ................................................................. 1 
Urban ................................................................ 2 
 
3 Facility catchment population  
 _______ people  
 
4 Average distance patients have to travel  
 _______ km  
 
5 Number of clinic days per week  
 _______ days  
 
6 Which days are clinic days? 
(Circle multiple if more than one clinic day) 
Monday ............................................................. 1 
Tuesday ............................................................ 2 
Wednesday ....................................................... 3 
Thursday ........................................................... 4 
Friday ................................................................ 5 
Saturday ........................................................... 6 
Sunday ............................................................. 7 
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 If applicable, which days are outreach 
days?  
(Circle multiple if more than one day) 
Monday ............................................................. 1 
Tuesday ............................................................ 2 
Wednesday ....................................................... 3 
Thursday ........................................................... 4 
Friday ................................................................ 5 
Saturday ........................................................... 6 
Sunday ............................................................. 7 
 
 If applicable, do you bring the Pima device 
on outreach visits? 
Yes ................................................................... 1 
No ..................................................................... 2 
 
7 Which days are patients able to receive a 
Pima CD4 test? 
(Circle multiple if more than one clinic day) 
Monday ............................................................. 1 
Tuesday ............................................................ 2 
Wednesday ....................................................... 3 
Thursday ........................................................... 4 
Friday ................................................................ 5 
Saturday ........................................................... 6 
Sunday ............................................................. 7 
 
8 How many hours a day is Pima available?  
 _______ hours  
 
9 Are you able to initiate every eligible 
patient? 
Yes ................................................................... 1 
No ..................................................................... 2 
 
  91 
 
10 If not, what percentage do you enrol? 0-25% ............................................................... 1 
25-50% ............................................................. 2 
50-75% ............................................................. 3 
75-100% ........................................................... 4 
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Lab Staff 
Please identify a lab staff who has experience using the Pima machine to answer the 
following questions: 
 Basic interviewee information Notes 
14 Person interviewed Lab technologist ............................................... 1 
Lab technician .................................................. 2 
Lab assistant .................................................... 3 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
15 How many people are currently staffed at 
this facility? (Write the number of each type 
of staff, if no staff, write 0) 
a.  
2a. _________ Lab technologist 
b.  
2b. __________ Lab technician 
c.  
2c. __________ Lab assistants 
 
 
16 Date staff trained on Pima machine  
|______|______| ______|  
 dd     /   mm    /    yy    . 
 
17 Date of first use on Pima machine  
|______|______| ______|  
 dd     /   mm    /    yy    . 
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18 Where is the Pima machine located? 
 
(Circle all that apply) 
Triage ............................................................... 1 
ART clinic ......................................................... 2 
ART clinician ..................................................... 3 
Lab .................................................................... 4 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
Sample Referrals 
19 What was your previous sample referral 
method? 
Sent to nearest health centre ............................ 1 
None ................................................................. 2 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
20 How many kilometres was the referral site 
(or nearest CD4 machine) 
 
 _______ km 
 
21 How long did it take for results to return to 
the clinic? 
 
 _______ days 
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 On which days did you collect samples? Monday ............................................................. 1 
Tuesday ............................................................ 2 
Wednesday ....................................................... 3 
Thursday ........................................................... 4 
Friday ................................................................ 5 
Saturday ........................................................... 6 
Sunday ............................................................. 7 
 
 How many samples did you collect per 
week 
 
                                    _________ samples 
 
 Were there more tests required than could 
be performed per week? If so, how many 
tests were required.  
Yes ................................................................... 1 
No ..................................................................... 1 
#_______________________________ 
 
24 Was there any time you couldn’t use the 
sample referral system? 
Yes ................................................................... 1 
No ..................................................................... 1 
 
Specify_______________________________ 
 
25 Did you have a CD4 logbook to record 
previous CD4 results?  
Yes ................................................................... 1 
No ..................................................................... 2 
 
26 Are you currently still using the sample 
referral method?  
Yes ................................................................... 1 
No ..................................................................... 2 
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27 If yes, why are you still using the sample 
referral method? (Circle all that apply, mark 
the most important with an arrow) 
High patient volumes ........................................ 1 
Broken Pima machine ....................................... 2 
More reliable and accurate ............................... 3 
More familiar ..................................................... 4 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
CD 4 Patient Flow and Volume 
28 Can you tell me how the Pima machine is 
used today starting with when a patient first 
arrives? 
  
29 Describe patient flow for PMTCT patient   
30 Describe patient flow for a patient from the 
CTC clinic 
  
31 Describe patient flow for a newly diagnosed 
HIV+ patient 
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33 How many patients do you receive each 
day currently? 
Clinic day Non-clinic day  
  
 How many Pima tests do you perform each 
day? 
_________ tests  
Quality Control 
35 When do you run the controls? Always before testing patients .......................... 1 
A few times a week  .......................................... 2 
Never ................................................................ 3 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
36 Any issues with running controls? No ..................................................................... 1 
Takes too long  ................................................. 2 
Machine not passing standards ........................ 3 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
CD4 Patient Flow 
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37 Who determines whether a patient needs a 
CD4 test? 
 
Triage ................................................................ 1 
ART clinic .......................................................... 2 
Lab .................................................................... 3 
OPD .................................................................. 4 
Maternity ........................................................... 5 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
39 Do patients have their HIV blue cards when 
they see the lab? 
Yes.................................................................... 1 
No ..................................................................... 2 
 
Specify_______________________________ 
 
 When a patient comes for a CD4 test, how 
long does the visit take? 
 
Specify_______________________________ 
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41 How do patients know their results are 
ready? 
Lab calls patient name ...................................... 1 
Lab waits for patient to return ........................... 2 
Triage staff finds the patient.............................. 3 
Next appointment day ....................................... 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
42 What is done with the CD4 result print-outs? Inserted into patient exercise book ................... 1 
Stapled into patient’s file ................................... 2 
Inserted into patient’s file .................................. 3 
Given to ART staff ............................................ 4 
Given to triage nurse ........................................ 5 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
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43 What do you do with the results if other staff 
are not available? 
Inserted into patient exercise book ................... 1 
Stapled into patient’s file ................................... 2 
Inserted into patient’s file .................................. 3 
Given to ART staff ............................................ 4 
Given to triage nurse ........................................ 5 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
44 Who explains the CD4 results to the patient 
for same-day results? 
Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
Records staff ..................................................... 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
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45 Who explains the CD4 results for non-
same-day results? 
Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
Records staff ..................................................... 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
46 Who records CD4 results into patient HIV 
blue cards? 
Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
Records staff ..................................................... 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
CD4 Resulting  
47 How often do you take samples using 
venous blood?  
Never ................................................................ 1 
Sometimes ........................................................ 2 
Always .............................................................. 3 
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48 Do you have a limit to how many patients 
you can test in day? If so, how many? 
Yes.................................................................... 1 
No ..................................................................... 2 
 
Specify_______________________________ 
 
49 How many patients do you have to turn 
away?  
 
 _______ patients 
 
50 How many patients are rescheduled for a 
different test date? 
 
 _______ patients 
 
51 Do patients leave due to waiting too long? If 
so, how many? 
Yes.................................................................... 1 
No ..................................................................... 2 
 
Specify_______________________________ 
 
52 Who receives same-day results? Everyone ........................................................... 1 
Urgent patients ................................................. 2 
Outside patients ................................................ 3 
Nobody ............................................................. 4 
 
Specify_______________________________ 
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53 What do you do when a patient cannot 
receive a CD4 test that day? 
All patients receive CD4 test ............................. 1 
Reschedule for non-clinic day ........................... 2 
Take venous blood and… 
Perform Pima test on a different day .. 3 
Use previous referral system .............. 4 
Ask to come on another day ............................. 5 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
54 Does the facility correctly use the CD4 
logbook? If not, why? 
Yes.................................................................... 1 
No ..................................................................... 2 
 
Specify_______________________________  
 
55 Did patients have to pay for CD4 tests 
before Pima?  
Yes.................................................................... 1 
No ..................................................................... 2 
 
56 Did patients have to pay for CD4 tests after 
Pima (currently)?  
Yes.................................................................... 1 
No ..................................................................... 2 
 
Supplies 
57 How many Pima tests do you use per 
month? 
 
_______ cartridges 
 
58 What was your initial supply of Pima kits? 
(Pima reagents + Pima supply) 
 
_______ cartridges 
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59 What is your current supply of Pima 
reagents? 
 
_______ cartridges 
 
60 What are the expiry dates of your Pima 
supplies? 
1.  
2.  
3. 
4. 
5. 
 
61 How often does the Pima machine not 
operate due to stock issue? 
Never ................................................................ 1 
Sometimes ........................................................ 2 
Always .............................................................. 3 
 
62 Do you know how to order Pima supplies Yes.................................................................... 1 
No ..................................................................... 2 
 
63 If they have ordered before, did the lab staff 
order correctly?  
Yes.................................................................... 1 
No ..................................................................... 2 
N/A .................................................................... 3 
 
 What are the stocks of the following 
supplies? 
  
11 HIV test kits Consistent stock ............................................... 1 
Stock challenges ............................................... 2 
Stock-outs ......................................................... 3 
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12 Cotrimoxazole  (Ceptrin) Consistent stock ............................................... 1 
Stock challenges ............................................... 2 
Stock-outs ......................................................... 3 
 
13 ARV drugs Consistent stock ............................................... 1 
Stock challenges ............................................... 2 
Stock-outs ......................................................... 3 
 
64 Do you use a stock card for Pima supplies?  Yes.................................................................... 1 
No ..................................................................... 2 
 
65 Did the lab staff use the stock card 
correctly?  
Yes.................................................................... 1 
No ..................................................................... 2 
N/A .................................................................... 3 
 
66 Has the Pima machine required 
troubleshooting?  
Yes.................................................................... 1 
No ..................................................................... 2 
 
67 Has the Pima machine needed to be 
swapped out for repairs?  
Yes.................................................................... 1 
No ..................................................................... 2 
 
68 If yes, how many days did it take?   
 _______ days 
 
69 How many times has the Pima machine 
required servicing? 
 
 _______ times 
 
70 How many days a week does the facility 
have power? 
 
 _______ days 
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71 How many days a week does the lab have 
power? 
 
 _______ days 
 
72 What type of power does the lab have? Grid ................................................................... 1 
Solar ................................................................. 2 
Generator .......................................................... 3 
None ................................................................. 4 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
 Do have a solar charger for the Pima? Yes.................................................................... 1 
No ..................................................................... 2 
 
73 Where do you charge the Pima machine? Lab .................................................................... 1 
ART clinic .......................................................... 2 
Computer room ................................................. 3 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
74 How often does the Pima machine not 
operate due to power issues? 
Never ................................................................ 1 
Sometimes ........................................................ 2 
Always .............................................................. 3 
 
75 Is the Pima machine fully charged every 
day?  
Yes.................................................................... 1 
No ..................................................................... 2 
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76 If not, why?  
 
(Circle all that apply, mark the most 
important with an arrow) 
Lack of consistent power .................................. 1 
Lack of coordination .......................................... 2 
Too many patients ............................................ 3 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
77 How many hours does the Pima machine 
last?  
 
 _______ hours 
 
78 How many days has the Pima machine 
been non-operational since you received it? 
 
 _______ days 
 
79 If so, what were the dates?  
 _______ dates 
 
Training  
80 Please describe the Pima training  
  
 
 How many people were trained to operate 
the Pima machine? 
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81 Who was trained on how to operate the 
Pima machine? 
Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________  
 
82 Who actually operates the Pima machine? Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________  
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83 Why doesn’t everyone who is trained to 
operate Pima actually operate the machine? 
Not part of job description ................................. 1 
Training was not sufficient ................................ 2 
Does not feel comfortable taking blood ............. 3 
Politics (Pima should be in lab) ......................... 4 
I don’t know ....................................................... 8 
Other (specify) .................................................. 9 
 
Specify_______________________________  
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Staff Perspectives  
  
Do you agree with the following 
statements? 
 
Circle the correct response  
Strongly 
Agree 
 
1 
Somewhat 
agree  
 
2 
Somewhat 
disagree  
 
3 
Strongly 
disagree  
 
4 
 
85 The training was sufficient to use the Pima 1 2 3 4  
86 The Pima is easy to use 1 2 3 4  
87 I am satisfied with having the Pima in this 
facility 
1 2 3 4  
88 Patients have been impacted by having the 
Pima here 
1 2 3 4  
89 The results from Pima are correct 1 2 3 4  
90 Using the Pima is preferable to the old 
system 
1 2 3 4  
Ask the following questions but not the answer choices. 
Circle the ones that apply and mark with an arrow the most important 
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91 What are some of the technical challenges 
to using the Pima machine?  
 
(Circle all that apply, mark the most 
important with an arrow) 
Throughput too low ........................................... 1 
Takes too long to shut down ............................. 2 
Won’t turn on .................................................... 3 
Doesn’t stay charged ........................................ 4 
Too many errors ............................................... 5 
Don’t trust the results ........................................ 6 
Difficult to collect finger-prick samples .............. 7 
None ................................................................. 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
92 What would you need in order to run more 
same-day tests each day?  
 
(Circle all that apply, mark the most 
important with an arrow) 
More staff .......................................................... 1 
More training ..................................................... 2 
More consistent power ...................................... 3 
Fewer other tasks ............................................. 4 
Second Pima machine ...................................... 5 
Better coordination ............................................ 6 
Schedule patients throughout week .................. 7 
None ................................................................. 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
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Pima vs. Previous Referral System 
93 What are the strengths of using Pima for 
CD4 testing as compared to the referral 
system? 
 
(Circle all that apply, mark the most 
important with an arrow) 
Same-day results .............................................. 1 
Easy to use ....................................................... 2 
Very fast ............................................................ 3 
Portable ............................................................ 4 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
94 What did you like about the referral system 
that is missing from Pima?  
 
(Circle all that apply, mark the most 
important with an arrow) 
More tests per week ......................................... 1 
Less complicated .............................................. 2 
Less work .......................................................... 3 
Better documentation ........................................ 4 
Referral incentive .............................................. 5 
More reliable results ......................................... 6 
Fewer invalid tests ............................................ 7 
None ................................................................. 8 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
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95 What challenges of the previous referral 
system were solved by the use of Pima? 
 
(Circle all that apply, mark the most 
important with an arrow) 
Same-day results .............................................. 1 
More tests per week ......................................... 2 
Less complicated .............................................. 3 
Less work .......................................................... 4 
Better documentation ........................................ 5 
Clearer processes ............................................. 6 
None ................................................................. 7 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
 
96 What gaps still exist that neither system 
addressed? 
 
(Circle all that apply, mark the most 
important with an arrow) 
Not enough tests run per day............................ 1 
Too complicated ............................................... 3 
Too much work ................................................. 4 
Not enough documentation ............................... 5 
Ambiguous processes ...................................... 6 
None ................................................................. 7 
Other (specify) .................................................. 9 
 
Specify_______________________________ 
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97 Are there any other issues you’d like to see 
addressed?  
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Interviewer Notes: 
98 Was this facility successful in implementing 
Pima?  
Yes.................................................................... 1 
No ..................................................................... 2 
Explain: 
 
99 Did the patient flow work to optimize Pima 
testing?  
Yes.................................................................... 1 
No ..................................................................... 2 
Explain: 
 
 
 
100 Was the facility successful in documenting 
CD4 results?  
Yes.................................................................... 1 
No ..................................................................... 2 
Explain: 
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101 Has Pima helped to increase access to CD4 
testing in this clinic?  
Yes.................................................................... 1 
No ..................................................................... 2 
Explain: 
 
 
 
 
 
102 What qualities contributed to the 
success/failure of the facility to implement 
and use Pima?  
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ART Staff 
Please identify an ART staff who has experience using the Pima machine to answer 
the following questions: 
 
 Basic interviewee information Notes 
103 Person interviewed ART Clinician .................................................... 1 
ART Nurse ........................................................ 2 
ART Nursing Assistant ...................................... 3 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
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104 How many people are currently staffed at 
this facility?  
 
(Write the number of each type of staff, if no 
staff, write 0) 
 
69. __________ ART Clinicians 
d.  
70. __________ ART Nurses 
 
71. __________ ART Nursing Assistants 
 
72. __________ Mentor Mothers 
 
73. __________ Facility-based expert clients 
 
74. __________ Clinicians 
 
75. __________ Records staff 
 
76. __________ Total Facility Staff  
 
 
CD4 testing  
105 How many patients do you usually have 
who need to see an ART clinician? 
Clinic day Non-clinic day  
 
 
 
 
106 Can you tell me how the Pima machine is 
used today starting with when a patient first 
arrives?  
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107 Who determines whether the patient needs 
a CD4 test? 
Triage ................................................................ 1 
ART nurse ......................................................... 2 
ART clinician ..................................................... 3 
Lab .................................................................... 4 
I don’t know ....................................................... 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
108 Who is responsible for recording CD4 
results in patient’s HIV blue card? 
Triage nurse ...................................................... 1 
ART clinic .......................................................... 2 
ART clinician ..................................................... 3 
Lab staff ............................................................ 4 
I don’t know ....................................................... 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
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129 Who counsels the patient after receiving the 
CD4 results? 
 
Lab staff ............................................................ 1 
Triage nurse ...................................................... 2 
Clinician............................................................. 3 
I don’t know ....................................................... 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
111 What do you do when a patient cannot 
receive a CD4 test that day? 
Reschedule for non-clinic day ........................... 1 
Ask patient to come a different day ................... 2 
Referred to other health clinic ........................... 3 
I don’t know ....................................................... 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
112 How did patients receive CD4 results with 
the previous sample referral system? 
Triage nurse enters into patient file ................... 1 
ART nurse enters into patient file ...................... 2 
Lab staff enters into patient file ......................... 3 
Records staff enters into patient file .................. 4 
I don’t know ....................................................... 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
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113 How often do patients receive same-day 
results? 
Never................................................................. 1 
Sometimes ........................................................ 2 
Always ............................................................... 3 
I don’t know ....................................................... 8 
 
Staff Perspectives  
  
Do you agree with the following 
statements? 
 
Circle the correct response  
Strongly 
Agree 
 
1 
Somewhat 
agree  
2 
Somewhat 
disagree  
3 
Strongly 
disagree  
4 
Don’t 
know or 
decline to 
answer 
114 The training was sufficient to use the Pima 1 2 3 4 5 
115 I am satisfied with having the Pima in this 
facility 
1 2 3 4 5 
116 Patients have been impacted by having the 
Pima here 
1 2 3 4 5 
117 The results from Pima are correct 1 2 3 4 5 
118 Using the Pima is preferable to the old 
system 
1 2 3 4 5 
Ask the following questions but not the answer choices. Circle the ones that apply and mark with an arrow the most 
important 
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119 What will help you to test more patients 
under current Pima constraints? 
 
(Circle all that apply, mark the most 
important with an arrow) 
More staff .......................................................... 1 
More training ..................................................... 2 
More consistent power ...................................... 3 
Fewer other tasks .............................................. 4 
Second Pima machine ...................................... 5 
Better coordination ............................................ 6 
Schedule patients throughout week .................. 7 
None ................................................................. 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
Pima vs. Previous Referral System 
120 What are the strengths of using Pima for 
CD4 testing over the referral system?  
 
(Circle all that apply, mark the most 
important with an arrow) 
Same-day results .............................................. 1 
Easy to use ....................................................... 2 
Very fast ............................................................ 3 
Portable ............................................................. 4 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
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121 What did you like about the previous referral 
system that is missing from Pima that you 
would like to see?  
 
(Circle all that apply, mark the most 
important with an arrow) 
More tests per week .......................................... 1 
Less complicated .............................................. 2 
Less work .......................................................... 3 
Better documentation ........................................ 4 
Referral incentive .............................................. 5 
More reliable results .......................................... 6 
Fewer invalid tests ............................................ 7 
None ................................................................. 8 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
122 What challenges from the previous referral 
system was solved by Pima? 
 
(Circle all that apply, mark the most 
important with an arrow) 
Same-day results .............................................. 1 
More tests per week .......................................... 2 
Less complicated .............................................. 3 
Less work .......................................................... 4 
Better documentation ........................................ 5 
Clearer processes ............................................. 6 
None ................................................................. 7 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
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123 What gaps still exist that neither system 
addressed? 
 
(Circle all that apply, mark the most 
important with an arrow) 
Not enough tests run per day ............................ 1 
Too complicated ................................................ 3 
Too much work .................................................. 4 
Not enough documentation ............................... 5 
Ambiguous processes ....................................... 6 
None ................................................................. 7 
Other (specify) ................................................... 9 
 
Specify_______________________________ 
 
124 Are there any other issues you’d like to see 
addressed?  
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IF HIV POSITIVE  IF ART ELIGIBLE 
Patient ID 
Patient Type  
(ART, 
PMTCT, …) 
Date HIV 
Rapid Test 
Performed 
Date 
Enrolled 
in CTC 
CD4 
count at 
time of 
diagnosis 
Date 
CD4 
Sample 
Collected 
ART 
Eligible? 
Was 
patient 
initiated? 
If so, date of 
ART 
Initiation 
TAT 
(Initiation-
Diagnosis, 
in days) 
LTFU 
(ART 
eligible, not 
initiated) 
TAT from CD4 Sample 
Given to ART Initiated 
(If Eligible) 
CD4 
Count at 
Initiation 
onto 
ART 
WHO Clinical 
Staging at 
Initiation onto 
ART 
                            
                            
                            
date 
confirmed 
HIV 
Pre-ART/ 
ART # 
Date of Pre-
ART/ ART # 
Date of 
request 
Date test 
performed 
Date 
result 
received 
CD4 
Result 
date 
medically 
eligible 
date eligible 
and ready 
Date of 
ART 
initiation 
Date of last 
visit 
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Appendix1.5:  Clinic Profiles. 
Basic Information Pima Implementation 
Clinic 
Name 
Location 
Information 
Part
ner 
Visit Date Supplies Staff Infrastructure Complementary 
Testing 
Notes 
Nanyamba 
HC 
Located in Mtwara 
Rural district, 100km 
from the nearest 
standard CD4 
machine. Catchment 
population of 6,710. 
On average, patients 
travel three hours by 
bicycle to reach the 
clinic.  
THP
S 
9 Oct 2012 Controls stocked out June 
18, local officials were 
unresponsive to requests for 
resupply. Initial and only 
delivery of Pima supplies 
occurred during the training.  
Staff has poor 
understanding of ordering 
process, has never placed an 
order for Pima supplies. 
Facility is understaffed;  
Staff requested more 
training esp. on 
supportive supervision, 
R&R forms, use of the 
CD4 logbook, and 
supply requisition  
Facility has both 
grid and solar 
power and has not 
experienced 
electrical-related 
delays for the Pima 
 
Clinic performs 
creatinine and 
Hb tests on-site, 
but has had stock 
problems with 
reagents. 
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Mchichira 
Dispensary  
Located in 
Tandahimba district, 
25 km from the 
nearest standard CD4 
machine. Catchment 
population of 9,147 
On average, patients 
travel one hour by 
bicycle to reach the 
clinic. 
 
THP
S 
9 Oct 2012 Initial and only delivery of 
Pima supplies occurred 
during the training. Staff has 
poor understanding of 
ordering process, has never 
placed an order for Pima 
supplies but has not stocked 
out because patient volumes 
are so low. Stock outs out of 
HIV test kits, Ceprin syrup, 
reagents, tubes, and ARVs. 
Critically understaffed, 
with 3 staff members 
and no laboratory staff.  
Staff report Pima 
training insufficient to 
cover necessary 
information. 
The facility uses 
solar power and 
has electricity 
except during the 
rainy season. 
 
Clinic ceased 
sample transport 
for liver function 
and creatinine 
testing when 
Pima device was 
placed. 
 
 
Rutamba 
HC 
Located in Lindi 
Rural district, 45km 
from nearest standard 
CD4 machine. 
Catchment pop. of 
8,011. On average, 
patients travel three 
hours by bicycle to 
reach the clinic.  
EGP
AF 
11 Oct 2012 Staff has poor 
understanding of ordering 
process for obtaining new 
reagents and cartridges. The 
clinic has never placed an 
order for Pima supplies but 
has not stocked out because 
the district delivers supplies 
routinely (push system).  
Facility is understaffed 
Staff report Pima 
training insufficient to 
cover necessary 
information particularly 
R&R, ordering, and 
correct use of the Pima 
(clinic running controls 
only weekly). 
The facility uses 
solar power and 
has electricity 
except during the 
rainy season. 
 
 Clinic was part of 
Pima pilot study in 
2011.  
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Basic Information 
 
Pima Implementation 
Clinic Name Location 
Information 
Partner Visit 
Date 
Supplies Staff Infrastructure Complementary 
Testing 
Notes 
Nanguwere Located in Mtwara 
Rural district, 32 km 
from the nearest 
standard CD4 
machine. Catchment 
population of 10,949. 
On average, patients 
travel one hour by 
bicycle to reach the 
clinic.  
THPS 10 Oct 
2012 
Initial and only delivery of 
Pima supplies occurred 
during the training. Staff has 
poor understanding of 
ordering process, has never 
placed an order for Pima 
supplies and has stocked out 
of Pima supplies, HIV test 
kits, reagents, tubes, and 
ARVs. 
Staffing pattern 
sufficient. Staff 
reported that Pima 
training did not cover 
necessary information 
particularly R&R, 
ordering, and correct 
use of the Pima (clinic 
running controls only 
weekly).  
The facility uses 
solar power and 
has electricity 
except during the 
rainy season. 
 
Clinic using 
sample transport 
for CD4 and 
biochemistry; 
logbook and 
results not 
available.  
DMO ordered clinic 
to use both FACS 
Calibur and Pima tests 
because MOH records 
supporting Pima 
placement at clinic 
unavailable. Pima 
only used for 6 weeks; 
nurses do not want to 
use two tests.  
Mahuta HC Located in 
Tandahimba district, 
100 km from the 
nearest standard CD4 
machine. Catchment 
population of 15,185. 
On average, patients 
THPS 10 Oct 
2012 
Staff has never placed an 
order for Pima supplies but 
receives supplies routinely 
from district officials. Seven 
month stock out of 
cartridges resulted after 
initial supply complete. 
Staffing pattern 
sufficient. Two staff 
trained on use of Pima, 
reported training 
session was too short to 
cover necessary 
The facility uses 
grid power and has 
had persistent 
problems with 
electrical supply. 
Local electricity 
company routinely 
Clinic ceased 
sample transport 
for liver function 
and creatinine 
testing when 
Pima device was 
Clinic had excellent 
data collection as 
compared to nearby 
clinics.   
Clinic received Pima 
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travel 2 hours by 
bicycle to reach the 
clinic.  
Stock outs out of HIV test 
kits, Ceprin syrup, reagents, 
tubes, and ARVs. 
information.  cuts power.  placed. 
 
in September 2011.  
Kisuju HC Located in Mkuranga 
district, 45 km from the 
nearest standard CD4 
machine. Catchment 
population of 6,685. On 
average, patients travel 
2 hours by bicycle to 
reach the clinic.  
THPS 24 Oct 
2012 
Clinic initially received 
supplies through push system 
from implementing partner. 
Clinicians aware of ordering 
process and will begin 
forecasting and ordering this 
quarter. HIV commodities and 
Pima supplies in stock.  
Staffing pattern sufficient. 
Reported training session 
was too short to cover 
necessary information. 
The facility uses 
solar power. Six 
month period of 
electricity failure led 
to complete stop of 
all POC testing in 
facility (Hemocue, 
Pima). 
Clinic received 
hematology and 
biochemistry POC 
machine. Current 
stock out of 
Vacuatainer tubes 
and prior 
electricity failure 
prevented device 
from being used.  
Clinic kept excellent 
records, including 
standard CD4 logbook 
produced by MOHSW.  
Clinic had excellent 
support from partner and 
local authorities. 
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Basic Information 
 
Pima Implementation 
Clinic 
Name 
Location 
Information 
Partner Visit 
Date 
Supplies Staff Infrastructure Complementary 
Testing 
Notes 
Mkamba 
HC 
Located in Mkuranga 
district, 60 km from 
the nearest standard 
CD4 machine. 
Catchment 
population of 17,174. 
On average, patients 
travel 1 hour by 
bicycle to reach the 
clinic.  
THPS 24 Oct 
2012 
Clinic initially received 
supplies through push 
system from implementing 
partner. Clinicians aware of 
ordering process and 
expected to begin 
forecasting and ordering this 
coming quarter. Pima has 
never been non-operational 
due to stock issues; other 
HIV commodities in stock. 
Staff shortages. Staff 
reports that Pima 
training was sufficient; 
they have yet to 
perform on-the job 
training for remaining 
staff.  
The facility uses 
solar power and 
has electricity even 
during the rainy 
season. Six month 
power failure this 
year resulted from 
solar battery 
failure.  
 
Clinic received 
hematology and 
biochemistry 
POC machine. 
Current stock out 
of Vacuatainer 
tubes and prior 
electricity failure 
have prevented 
device from 
being used.  
 
Mkuzi HC Located in Muheza 
district, 10 km from 
the nearest standard 
CD4 machine. 
Catchment 
population of 16,329. 
AIDS 
Relief 
18 Oct 
2012 
Clinic initially received 
stock through push system 
from MSD. Staff has since 
been educated on ordering 
process, expected to forecast 
and order own supplies 
Staff shortages; all staff 
initially trained to use 
Pima have since left the 
facility. Staff requested 
four-day Pima training, 
and clarification on 
The facility uses 
grid power. Due to 
power rationing 
they have 
inconsistent 
Clinic ceased 
sample transport 
for liver function 
and creatinine 
testing when 
Pima device was 
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On average, patients 
travel 1 hour by 
bicycle to reach the 
clinic.  
moving forward. Clinic has 
already placed order for new 
supplies. Consistent stock of 
Pima and HIV supplies.  
supportive supervision, 
R&R, record keeping, 
and ordering.  
electricity.  placed. 
Mwera HC Located in Pangani 
district, 11 km from 
the nearest standard 
CD4 machine. 
Catchment 
population of 7,791. 
On average, patients 
travel three hours by 
bicycle to reach the 
clinic.  
AIDS 
Relief 
18 Oct 
2012 
Clinic initially received 
stock through push system 
from MSD. Staff has since 
been educated on ordering 
process, expected to forecast 
and order own supplies 
moving forward. Clinic has 
already placed order for new 
supplies. Consistent stock of 
Pima and HIV supplies. 
Staff shortages. Staff 
requested four-day 
Pima training, and 
clarification on 
supportive supervision, 
R&R, record keeping, 
and ordering. 
 Clinic ceased 
sample transport 
for liver function 
and creatinine 
testing when 
Pima device was 
placed. Clinic 
refers patients to 
hospitals for 
testing.  
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Basic Information 
 
Pima Implementation 
Clinic 
Name 
Location 
Information 
Partner Visit 
Date 
Supplies Staff Infrastructure Complementary 
Testing 
Notes 
Kabuku 
HC 
Located in Handeni 
district, 78 km from 
the nearest standard 
CD4 machine. 
Catchment 
population of 46,213. 
On average, patients 
travel 3 hours by 
bicycle to reach the 
clinic.  
AIDS 
Relief 
17 Oct 
2012 
Clinic receives stock 
through push system from 
MSD. One-month stock out 
of controls resulted in 
August 2012. Staffs do not 
understand ordering or 
process for obtaining new 
reagents and cartridges for 
Pima device. Staff has never 
placed an order for Pima 
supplies. 
Staffing pattern 
sufficient. Staff 
requested longer Pima 
training, including 
clarification on 
supportive supervision, 
R&R, record keeping, 
and ordering. Trained 
staff provided on-the-
job training to all 
remaining staff.  
The facility uses 
grid power. Due to 
power rationing 
they have 
inconsistent access 
to electricity.  
Clinic ceased 
sample transport 
for liver function 
and creatinine 
testing when 
Pima device was 
placed, refers 
clients to 
hospital for 
testing.  
 
 
 
 
